Tissue engineering for traumatic spinal cord injury: Research advances and clinical translation Authors: Chengcheng Luan, Dong Ming, Xiaosong Gu Published: 2026 ABSTRACT Traumatic spinal cord injury (TSCI) typically leads to persistent motor and sensory deficits. Interdisciplinary advances have supported preclinical research into tissue engineering approaches for TSCI repair, with the core objective of reconstructing damaged neural tissue and restoring both anatomical integrity and physiological neural function. Many published reviews provide only a descriptive categorization of biomaterials, without establishing a systematic design logic aligned with stepwise pathological shifts after TSCI. This review summarizes tissue engineering interventions for TSCI and develops a biomaterial design system tailored to distinct phases of pathological injury. It elucidates intrinsic connections among material structure, physicochemical properties, and in vivo biological performance. This work further examines appropriate animal model selection and practical hurdles that restrict the bench-to-clinic translation of preclinical therapeutic effects. Finally, it identifies key bottlenecks hindering clinical translation and provides theoretical ideas for the development of neural regenerative biomaterials and the translational research of TSCI repair. Introduction Traumatic spinal cord injury (TSCI) and non-traumatic spinal cord injury (NTSCI) represent two distinct etiological categories of spinal cord damage. TSCI typically results from external physical forces that cause vertebral fractures or dislocations, leading to spinal cord laceration, rupture, or compression, whereas NTSCI is driven primarily by tumors, infections, or degenerative diseases [1,2]. A 2024 meta-analysis reported a weighted global pooled incidence of 23.77 per million for all spinal cord injuries (SCI). Stratified subgroup analysis yielded distinct incidence estimates of 26.48 per million for TSCI and 17.93 per million for NTSCI [3]. After TSCI, acute mechanical trauma rapidly disrupts local blood vessels and induces acute neuronal loss, which subsequently initiates long-lasting secondary pathological cascades [4]. These complex pathological changes, combined with the limited intrinsic regenerative capacity of the central nervous system (CNS), severely impede effective tissue repair. Over the past decade, multiple regenerative approaches, including stem cell therapy, biomaterial fabrication, gene editing, and brain–computer interfaces, have been developed for SCI treatment. Many of these interventions have achieved favorable therapeutic outcomes in rodent and non-human primate models and have entered early-stage clinical trials. Among these, tissue engineering platforms, encompassing biological scaffolds, hydrogels, nanoparticles, and spinal cord organoids (SCOs), have matured rapidly, offering compelling translational potential [5]. By integrating cell biology, materials science, and clinical medicine, tissue engineering seeks to replace or repair damaged tissue and restore neurological function [6]. However, existing review papers on TSCI biomaterials mostly follow a material-centric narrative structure. These works commonly classify biomaterial types and briefly describe their applicable scenarios, yet rarely establish systematic correlations between progressive TSCI pathological processes and customized biomaterial design criteria. In addition, the existing summary lacks a detailed exploration of clinical studies and their translational limitations. To address this research gap, the present review establishes a matching relationship between the staged pathological characteristics of TSCI and targeted biomaterial design specifications. We systematically classify natural and synthetic biomaterials and their functionalized derivatives and evaluate four core tissue-engineering platforms: nanoparticles, hydrogels, biological scaffolds, and SCOs. We analyze intrinsic correlations among material structure, physicochemical properties, and in vivo biological performance; discuss rational animal model selection; recapitulate preclinical translational efforts; dissect practical barriers that limit bench-to-clinic translation of therapeutic efficacy; and propose rational design strategies for advanced biomaterials that meet the demands of distinct TSCI pathological phases. TSCI pathological mechanisms and matched tissue engineering systems The pathophysiology of TSCI propagates through two sequential stages: primary and secondary injury. Distinct differences exist in the injury microenvironment, cellular behavior, inflammatory status, and tissue remodeling features across all TSCI stages. Conventional single-functional repair materials fail to adapt to dynamically changing pathological demands throughout the entire TSCI pathological cycle, which is the primary cause of unsatisfactory nerve repair efficacy [7]. Accordingly, precisely matching functional biomaterials to the staged pathological features of sequential TSCI lesions is a pivotal research direction for achieving targeted intervention, preventing progressive injury, and facilitating orderly nerve regeneration [8]. This chapter systematically elaborates on the core pathological features of TSCI, covering the primary injury and the acute, subacute, and chronic stages. It clarifies the essential functions of repair materials required at each stage and summarizes compatible material systems, key performance indicators, and targeted modification strategies. These analyses lay solid theoretical foundations for the development and translational application of biomaterials for precise TSCI repair. Pathophysiology of TSCI Primary injury, initiated directly by mechanical trauma, manifests as acute vascular rupture, blood–spinal cord barrier (BSCB) disruption, neuronal necrosis, and axonal shearing, with the magnitude of this initial insult largely dictating the ultimate neurological outcome [9]. Subsequently, secondary injury unfolds as a protracted, multi-phase pathological cascade, classified chronologically into acute, subacute, and chronic phases [7]. The acute phase is marked by hemorrhage, BSCB breakdown, and a robust neuroinflammatory response driven by infiltrating neutrophils and macrophages. Cytotoxic molecules released at the injury site exacerbate neuronal and glial cell death [10]. During the subacute phase, microglia and astrocytes are activated. Microglia secrete inflammatory mediators to modulate neuroinflammation, whereas astrocytes initiate glial scar formation. The activation of these glial populations exerts both detrimental and beneficial effects on injury repair [11]. By the chronic phase, the lesion core has developed into a fluid-filled cystic cavity walled off by a dense astrocytic and fibroblastic scar, infiltrated by microglia and macrophages [12] (Fig. 1). This complex pathophysiological cascade of secondary injury may precipitate additional tissue damage and neurological dysfunction [13,14]. Together, these pathological changes establish a hostile microenvironment that suppresses axonal regrowth, representing the central obstacle to spinal cord repair [15]. In chronic TSCI, dense scar tissue covers the lesion area and impedes cell migration and angiogenesis; complete TSCI leads to more severe cystic cavitation and scar formation, making repair extremely difficult [16].Fig. 1Schematic illustration of the pathophysiological cascade after TSCI. Primary injury results in immediate mechanical damage, including hemorrhage, axonal disruption, and neuronal loss. Secondary injury evolves through three distinct phases: an acute phase characterized by robust inflammation, oxidative stress, and immune cell infiltration; a subacute phase dominated by reactive astrogliosis, microglial activation, and early fibroblast recruitment; and a chronic phase marked by dense glial-fibrotic scar formation, cystic cavitation, and permanent neural circuit disruption. Schematic illustration of the pathophysiological cascade after TSCI. Primary injury results in immediate mechanical damage, including hemorrhage, axonal disruption, and neuronal loss. Secondary injury evolves through three distinct phases: an acute phase characterized by robust inflammation, oxidative stress, and immune cell infiltration; a subacute phase dominated by reactive astrogliosis, microglial activation, and early fibroblast recruitment; and a chronic phase marked by dense glial-fibrotic scar formation, cystic cavitation, and permanent neural circuit disruption. Biomaterials adaptation system Formulating pathology-adapted tissue engineering strategies tailored to the pathological demands and repair bottlenecks at each stage following TSCI, and constructing staged biomaterial systems for precise repair, represents a vital developmental direction for treatment (Fig. 2) [17].Fig. 2Schematic matching system of tissue engineering strategies targeting distinct pathological stages of TSCI. This framework illustrates the hierarchical correspondence between stage-specific repair demands of TSCI lesions and the tailored physicochemical, mechanical, and functional characteristics of biomaterial scaffolds deployed for each injury phase. Schematic matching system of tissue engineering strategies targeting distinct pathological stages of TSCI. This framework illustrates the hierarchical correspondence between stage-specific repair demands of TSCI lesions and the tailored physicochemical, mechanical, and functional characteristics of biomaterial scaffolds deployed for each injury phase. Primary injury Primary injury develops within seconds and is characterized by irreversible disruption of intrinsic tissue architecture [18]. Early intervention at this phase aims to prevent the cascade of secondary injury and preserve residual neural function [19]. Accordingly, applied biomaterials are required to deliver immediate protection and halt progressive damage, which includes five core functions: providing mechanical stability and avoiding secondary trauma [14], sealing the compromised BSCB to reduce tissue exudation and edema [20], rapidly blocking damaged microvessels to achieve hemostasis and prevent hematoma accumulation [21,22], maintaining excellent biocompatibility to protect vulnerable tissues [23], and inhibiting the initial activation of reactive oxygen species and pro-inflammatory factors to cut off the onset of secondary injury [[24], [25], [26]]. For such requirements, biomaterials with rapid curing capability and superior biosafety are the optimal choices [27]. These biomaterials need to satisfy a series of key performance requirements. They should achieve rapid gelation, possess favorable biological safety without hemolysis and inflammatory responses, and exhibit low stiffness and high flexibility to match the mechanical properties of spinal tissues. Additionally, the materials are expected to provide effective hemostasis and gradually degrade after their protective functions are complete. Secondary injury Secondary injury mainly consists of three stages: acute, subacute, and chronic, and different pathological challenges dictate biomaterial design. Acute phase Biomaterials used in acute TSCI are designed to mitigate secondary damage and safeguard neural tissue from severe oxidative stress, excessive inflammation, tissue edema, and extensive neuronal apoptosis [28]. Their core functions encompass ROS clearance, interruption of secondary injury cascades, restoration of the BSCB, moderate hemostasis, and sustained release of neuroprotective factors [[29], [30], [31]]. Meanwhile, these biomaterials maintain favorable biocompatibility, preventing irritation of delicate lesions. Injectable natural polymers, such as hyaluronic acid, alginate, and chitosan; degradable functional hydrogels; antioxidant nanocomposite hydrogels; and anti-inflammatory hemostatic dressings are preferred choices [32]. Targeted modifications, including the incorporation of antioxidant components and anti-inflammatory factors as well as the grafting of adhesive bioactive moieties, are employed to enhance their antioxidative, anti-inflammatory, hemostatic, and barrier-repairing capabilities. Subacute phase Repair for subacute TSCI relies on four core demands. It requires balancing the local immune microenvironment to ease persistent mild inflammation moderately, adjusting glial proliferation to lower early glial scar barriers, triggering directed differentiation of neural stem cells and orderly axonal outgrowth, and advancing angiogenesis and vascular maturation to sustain cell adhesion, proliferation, and migration [[33], [34], [35], [36]]. Precise matching of repair requirements can be achieved through a compatible biomaterial system and a targeted modification process [37]. For example, bionic micropatterned scaffolds can be fabricated with mechanical properties that match those of native spinal cord tissue [38]. After implantation, such scaffolds reduce mechanical stimulation of residual neural tissue [39]. Their well-defined micropatterns guide cellular alignment and axonal regeneration. A highly interconnected, through-pore architecture facilitates cell infiltration and efficient exchange of nutrients and metabolites, thereby optimizing the local microenvironment to support angiogenesis and neural tissue remodeling [[40], [41], [42]]. Neurotrophic or anti-inflammatory factors incorporated into the scaffold maintain stable biological activity over an extended period, thereby inhibiting neuronal apoptosis and mitigating persistent local inflammation [43,44]. Collectively, this strategy enables sustained promotion of neural tissue regeneration and significantly enhances both tissue repair and functional recovery during the subacute phase of traumatic spinal cord injury [[45], [46], [47]]. Chronic phase Biomaterials for the chronic phase primarily aim to eliminate regenerative barriers and restore neural function by addressing dense glial scars, cystic defects, and inhibitory lesion microenvironments [48]. The core therapeutic requirements include removing scar-related physical and chemical barriers to regeneration, repairing cystic spinal defects and reconstructing intact tissue structure, promoting long-distance axonal regeneration and remyelination via sustained neurotrophic support, and maintaining long-term lesion microenvironmental homeostasis [49]. To address these intricate repair requirements, mechanically robust biomimetic composite scaffolds serve as ideal carriers for chronic TSCI repair and align with the slow tissue remodeling characteristic of the chronic stage. Scaffolds with aligned internal channels guide axonal extension across glial scar tissue [13,50]. Bioactive factors, combined with stem cells, exert synergistic neuroprotective and regenerative effects that are vital for repair at the chronic stage [51]. In addition, inflammation and pH-responsive delivery systems dynamically match the protracted tissue remodeling cascade, thereby greatly facilitating neural tissue reconstruction and motor functional recovery after chronic TSCI [52]. Single-phase treatment strategies can only produce limited overall therapeutic effects. Targeting the specific pathological characteristics of each injury stage to implement multistage, personalized interventions has become a promising direction for effective TSCI repair [23,27]. The above content provides a solid theoretical basis for the screening and functional modification of stage-specific biomaterials [53]. Animal models of TSCI To accurately recapitulate human TSCI pathophysiology and evaluate therapeutic efficacy and translational potential, researchers have established diverse animal models [54]. This section systematically reviews mainstream animal models and experimental approaches used in TSCI research. It comprehensively compares these models with respect to pathological features, applicable scenarios, inherent limitations, and corresponding tissue engineering intervention strategies (Table 1) [[69], [70], [71], [72]]. The core focus is to evaluate the consistency between different TSCI modeling methods and the pathological characteristics of clinical TSCI. Specifically, we summarize the unique strengths and limitations of contusion, compression, transection, and stretch models in recapitulating human TSCI pathophysiology. This chapter further explores multiple factors contributing to variable outcomes in animal experiments, including model selection, injury severity, and intervention timing. It also discusses key challenges impeding the clinical translation of current preclinical TSCI models. By clarifying the optimal research scope for each model, this work provides practical references and guidance for the rational design of biomaterials and the standardized planning of subsequent TSCI experiments.Table 1Animal models of TSCI.Table 1ModelsMethods and EquipmentAdvantages and disadvantagesRelevance of clinical translationPathophysiological cascade reactionTreatment approach of tissue engineeringRefs.ContusionNew York University (NYU) impactor●Mature technology●Standardizes injury severity●Favorable reproducibility●No real-time force monitoring●Requires laminectomy●Highest clinical relevance●High reproducibility●Gold standard for biomaterial evaluation●Suitable for quantitative biomechanical studies●Closely mimics human TSCI●Ideal for preclinical therapeutic screening●Primary injuries: hemorrhage; edema; axonal injury; neuronal death, etc.●Secondary injury: Microglial and astrocytic activation and proliferation; Neuroinflammatory response; Glial scar formation; Cystic cavitation; Demyelination; Neuronal and oligodendrocyte apoptosis●Injectable hydrogels●Nanoparticle-delivery systems●Electrospun/3D-printed aligned scaffolds●Decellularized extracellular matrix (dECM)●Conductive/piezoelectric/magneto-responsive materials●Spinal cord organoid-biomaterial composites●Sustained-release factor/gene delivery systems[25,[55], [56], [57]]Ohio State University (OSU) impactor●Tissue-adaptive control●Precise force/displacement modulation●Complex calibration●Low operability●Requires laminectomyMASCIS Impactor Model III●Standardized parameters●High reproducibility●High cost●Bulky equipment●Requires laminectomyInfinite Horizon (IH) impactor●Motion artifact elimination●High reliability●Narrow force range●High experimental cost●Requires laminectomyCrushFogarty catheter●Minimal soft tissue dissection and bone removal●Easy to handle●Fast procedure●Low operator experience required●Mimics spinal cord compression in unrepaired dislocation or fracture-dislocation●Mimics acute compressive SCI●Good for decompression studies●Reflects slow-compressing lesions: tumors, spondylitis, metastases●Creates chronic compression injury●Mimics delayed cervical myelopathy●Produces graded injury (mild/moderate/severe)●Reduces surgical adverse effects●Primary injury: Spinal cord hemorrhagic necrosis; Axonal disruption●Secondary injury: Microglia polarization; Glial Scar Formation;●Demyelination; Neuroinflammation●Injectable adhesive hydrogels●Self-healing hydrogels, sustained-release nanocarriers●Mechanically matched flexible scaffolds●Injectable dECM microgels●Stem cell/exosome delivery systems●Anti-fibrotic anti-adhesion materials[[58], [59], [60], [61]]ModifiedAneurysms or vascularclips●Simple operation●Low cost●Avoids biomechanical problems of impact modelsScrew compression model●No laminectomy required●Preserves spinal cord hydrodynamics●Increased infectionSpacer●Precise and reproducible●Retained or removed surgicallyspinal cordstrapping●Minimally invasive and safe●Difficult to generate uniform trauma●Reproducibility unvalidatedTransectionComplete transection●Clinical cases rare●Standardized protocol●Ideal for regeneration and tissue engineering studies●Eliminates supraspinal input●Limited clinical relevance●Risk of overestimating bridging efficacy●Useful for pain and partial pathway regeneration studies●Good for neurotechnology and motor recovery studies●Primary injury: Spinal cord hemorrhage; Axonal injury; Neuronal death; Spinal shock●Secondary injury: Neuroinflammation; Glial scar formation; Degeneration of the distal axon segment; Axon severing●Aligned bridging scaffolds●3D-printed oriented scaffolds●Electrospun fibrous scaffolds●Conductive electroactive scaffolds●SCOs/neural relay constructs●Cell-laden bridge systems●Neurotrophic factor delivery systems[[62], [63], [64]]PartialTransection (hemisections)●Standardized and reproducible protocolStaggered hemisections●Complete motor paralysis without full transection●Well-controlled and reproducible●Limited spontaneous recovery●Autonomic functions sparedTractionLateral dislocation●Stable experimental parameters●Large inter-individual differences●High clinical relevance●Mimics traumatic fracture–dislocation●Suitable for translational research●Primary injury: Vascular disruption; Axonal shearing●Secondary injury: Microglial and astrocyte activation; Neuroinflammatory response; Neurofilament dephosphorylation; progressive expansion of axonal damage●Mechanically compliant stretchable hydrogels●Neuroprotective antioxidant nanocarriers●Flexible low-modulus aligned scaffolds●Myelin-regenerative cell delivery systems●Injectable dECM microgels●Neurotrophic factor sustained-release systems[[65], [66], [67], [68]] Table 1Animal models of TSCI.Table 1ModelsMethods and EquipmentAdvantages and disadvantagesRelevance of clinical translationPathophysiological cascade reactionTreatment approach of tissue engineeringRefs.ContusionNew York University (NYU) impactor●Mature technology●Standardizes injury severity●Favorable reproducibility●No real-time force monitoring●Requires laminectomy●Highest clinical relevance●High reproducibility●Gold standard for biomaterial evaluation●Suitable for quantitative biomechanical studies●Closely mimics human TSCI●Ideal for preclinical therapeutic screening●Primary injuries: hemorrhage; edema; axonal injury; neuronal death, etc.●Secondary injury: Microglial and astrocytic activation and proliferation; Neuroinflammatory response; Glial scar formation; Cystic cavitation; Demyelination; Neuronal and oligodendrocyte apoptosis●Injectable hydrogels●Nanoparticle-delivery systems●Electrospun/3D-printed aligned scaffolds●Decellularized extracellular matrix (dECM)●Conductive/piezoelectric/magneto-responsive materials●Spinal cord organoid-biomaterial composites●Sustained-release factor/gene delivery systems[25,[55], [56], [57]]Ohio State University (OSU) impactor●Tissue-adaptive control●Precise force/displacement modulation●Complex calibration●Low operability●Requires laminectomyMASCIS Impactor Model III●Standardized parameters●High reproducibility●High cost●Bulky equipment●Requires laminectomyInfinite Horizon (IH) impactor●Motion artifact elimination●High reliability●Narrow force range●High experimental cost●Requires laminectomyCrushFogarty catheter●Minimal soft tissue dissection and bone removal●Easy to handle●Fast procedure●Low operator experience required●Mimics spinal cord compression in unrepaired dislocation or fracture-dislocation●Mimics acute compressive SCI●Good for decompression studies●Reflects slow-compressing lesions: tumors, spondylitis, metastases●Creates chronic compression injury●Mimics delayed cervical myelopathy●Produces graded injury (mild/moderate/severe)●Reduces surgical adverse effects●Primary injury: Spinal cord hemorrhagic necrosis; Axonal disruption●Secondary injury: Microglia polarization; Glial Scar Formation;●Demyelination; Neuroinflammation●Injectable adhesive hydrogels●Self-healing hydrogels, sustained-release nanocarriers●Mechanically matched flexible scaffolds●Injectable dECM microgels●Stem cell/exosome delivery systems●Anti-fibrotic anti-adhesion materials[[58], [59], [60], [61]]ModifiedAneurysms or vascularclips●Simple operation●Low cost●Avoids biomechanical problems of impact modelsScrew compression model●No laminectomy required●Preserves spinal cord hydrodynamics●Increased infectionSpacer●Precise and reproducible●Retained or removed surgicallyspinal cordstrapping●Minimally invasive and safe●Difficult to generate uniform trauma●Reproducibility unvalidatedTransectionComplete transection●Clinical cases rare●Standardized protocol●Ideal for regeneration and tissue engineering studies●Eliminates supraspinal input●Limited clinical relevance●Risk of overestimating bridging efficacy●Useful for pain and partial pathway regeneration studies●Good for neurotechnology and motor recovery studies●Primary injury: Spinal cord hemorrhage; Axonal injury; Neuronal death; Spinal shock●Secondary injury: Neuroinflammation; Glial scar formation; Degeneration of the distal axon segment; Axon severing●Aligned bridging scaffolds●3D-printed oriented scaffolds●Electrospun fibrous scaffolds●Conductive electroactive scaffolds●SCOs/neural relay constructs●Cell-laden bridge systems●Neurotrophic factor delivery systems[[62], [63], [64]]PartialTransection (hemisections)●Standardized and reproducible protocolStaggered hemisections●Complete motor paralysis without full transection●Well-controlled and reproducible●Limited spontaneous recovery●Autonomic functions sparedTractionLateral dislocation●Stable experimental parameters●Large inter-individual differences●High clinical relevance●Mimics traumatic fracture–dislocation●Suitable for translational research●Primary injury: Vascular disruption; Axonal shearing●Secondary injury: Microglial and astrocyte activation; Neuroinflammatory response; Neurofilament dephosphorylation; progressive expansion of axonal damage●Mechanically compliant stretchable hydrogels●Neuroprotective antioxidant nanocarriers●Flexible low-modulus aligned scaffolds●Myelin-regenerative cell delivery systems●Injectable dECM microgels●Neurotrophic factor sustained-release systems[[65], [66], [67], [68]] Animal models of TSCI. ●Mature technology ●Mature technology ●Standardizes injury severity ●Standardizes injury severity ●Favorable reproducibility ●Favorable reproducibility ●No real-time force monitoring ●No real-time force monitoring ●Requires laminectomy ●Requires laminectomy ●Highest clinical relevance ●Highest clinical relevance ●High reproducibility ●High reproducibility ●Gold standard for biomaterial evaluation ●Gold standard for biomaterial evaluation ●Suitable for quantitative biomechanical studies ●Suitable for quantitative biomechanical studies ●Closely mimics human TSCI ●Closely mimics human TSCI ●Ideal for preclinical therapeutic screening ●Ideal for preclinical therapeutic screening ●Primary injuries: hemorrhage; edema; axonal injury; neuronal death, etc. ●Primary injuries: hemorrhage; edema; axonal injury; neuronal death, etc. ●Secondary injury: Microglial and astrocytic activation and proliferation; Neuroinflammatory response; Glial scar formation; Cystic cavitation; Demyelination; Neuronal and oligodendrocyte apoptosis ●Secondary injury: Microglial and astrocytic activation and proliferation; Neuroinflammatory response; Glial scar formation; Cystic cavitation; Demyelination; Neuronal and oligodendrocyte apoptosis ●Injectable hydrogels ●Injectable hydrogels ●Nanoparticle-delivery systems ●Nanoparticle-delivery systems ●Electrospun/3D-printed aligned scaffolds ●Electrospun/3D-printed aligned scaffolds ●Decellularized extracellular matrix (dECM) ●Decellularized extracellular matrix (dECM) ●Conductive/piezoelectric/magneto-responsive materials ●Conductive/piezoelectric/magneto-responsive materials ●Spinal cord organoid-biomaterial composites ●Spinal cord organoid-biomaterial composites ●Sustained-release factor/gene delivery systems ●Sustained-release factor/gene delivery systems [25,[55], [56], [57]] [25,[55], [56], [57]] ●Tissue-adaptive control ●Tissue-adaptive control ●Precise force/displacement modulation ●Precise force/displacement modulation ●Complex calibration ●Complex calibration ●Low operability ●Low operability ●Requires laminectomy ●Requires laminectomy ●Standardized parameters ●Standardized parameters ●High reproducibility ●High reproducibility ●High cost ●High cost ●Bulky equipment ●Bulky equipment ●Requires laminectomy ●Requires laminectomy ●Motion artifact elimination ●Motion artifact elimination ●High reliability ●High reliability ●Narrow force range ●Narrow force range ●High experimental cost ●High experimental cost ●Requires laminectomy ●Requires laminectomy ●Minimal soft tissue dissection and bone removal ●Minimal soft tissue dissection and bone removal ●Easy to handle ●Easy to handle ●Fast procedure ●Fast procedure ●Low operator experience required ●Low operator experience required ●Mimics spinal cord compression in unrepaired dislocation or fracture-dislocation ●Mimics spinal cord compression in unrepaired dislocation or fracture-dislocation ●Mimics acute compressive SCI ●Mimics acute compressive SCI ●Good for decompression studies ●Good for decompression studies ●Reflects slow-compressing lesions: tumors, spondylitis, metastases ●Reflects slow-compressing lesions: tumors, spondylitis, metastases ●Creates chronic compression injury ●Creates chronic compression injury ●Mimics delayed cervical myelopathy ●Mimics delayed cervical myelopathy ●Produces graded injury (mild/moderate/severe) ●Produces graded injury (mild/moderate/severe) ●Reduces surgical adverse effects ●Reduces surgical adverse effects ●Primary injury: Spinal cord hemorrhagic necrosis; Axonal disruption ●Primary injury: Spinal cord hemorrhagic necrosis; Axonal disruption ●Secondary injury: Microglia polarization; Glial Scar Formation; ●Secondary injury: Microglia polarization; Glial Scar Formation; ●Demyelination; Neuroinflammation ●Demyelination; Neuroinflammation ●Injectable adhesive hydrogels ●Injectable adhesive hydrogels ●Self-healing hydrogels, sustained-release nanocarriers ●Self-healing hydrogels, sustained-release nanocarriers ●Mechanically matched flexible scaffolds ●Mechanically matched flexible scaffolds ●Injectable dECM microgels ●Injectable dECM microgels ●Stem cell/exosome delivery systems ●Stem cell/exosome delivery systems ●Anti-fibrotic anti-adhesion materials ●Anti-fibrotic anti-adhesion materials [[58], [59], [60], [61]] [[58], [59], [60], [61]] ●Simple operation ●Simple operation ●Low cost ●Low cost ●Avoids biomechanical problems of impact models ●Avoids biomechanical problems of impact models ●No laminectomy required ●No laminectomy required ●Preserves spinal cord hydrodynamics ●Preserves spinal cord hydrodynamics ●Increased infection ●Increased infection ●Precise and reproducible ●Precise and reproducible ●Retained or removed surgically ●Retained or removed surgically ●Minimally invasive and safe ●Minimally invasive and safe ●Difficult to generate uniform trauma ●Difficult to generate uniform trauma ●Reproducibility unvalidated ●Reproducibility unvalidated ●Clinical cases rare ●Clinical cases rare ●Standardized protocol ●Standardized protocol ●Ideal for regeneration and tissue engineering studies ●Ideal for regeneration and tissue engineering studies ●Eliminates supraspinal input ●Eliminates supraspinal input ●Limited clinical relevance ●Limited clinical relevance ●Risk of overestimating bridging efficacy ●Risk of overestimating bridging efficacy ●Useful for pain and partial pathway regeneration studies ●Useful for pain and partial pathway regeneration studies ●Good for neurotechnology and motor recovery studies ●Good for neurotechnology and motor recovery studies ●Primary injury: Spinal cord hemorrhage; Axonal injury; Neuronal death; Spinal shock ●Primary injury: Spinal cord hemorrhage; Axonal injury; Neuronal death; Spinal shock ●Secondary injury: Neuroinflammation; Glial scar formation; Degeneration of the distal axon segment; Axon severing ●Secondary injury: Neuroinflammation; Glial scar formation; Degeneration of the distal axon segment; Axon severing ●Aligned bridging scaffolds ●Aligned bridging scaffolds ●3D-printed oriented scaffolds ●3D-printed oriented scaffolds ●Electrospun fibrous scaffolds ●Electrospun fibrous scaffolds ●Conductive electroactive scaffolds ●Conductive electroactive scaffolds ●SCOs/neural relay constructs ●SCOs/neural relay constructs ●Cell-laden bridge systems ●Cell-laden bridge systems ●Neurotrophic factor delivery systems ●Neurotrophic factor delivery systems [[62], [63], [64]] [[62], [63], [64]] ●Standardized and reproducible protocol ●Standardized and reproducible protocol ●Complete motor paralysis without full transection ●Complete motor paralysis without full transection ●Well-controlled and reproducible ●Well-controlled and reproducible ●Limited spontaneous recovery ●Limited spontaneous recovery ●Autonomic functions spared ●Autonomic functions spared ●Stable experimental parameters ●Stable experimental parameters ●Large inter-individual differences ●Large inter-individual differences ●High clinical relevance ●High clinical relevance ●Mimics traumatic fracture–dislocation ●Mimics traumatic fracture–dislocation ●Suitable for translational research ●Suitable for translational research ●Primary injury: Vascular disruption; Axonal shearing ●Primary injury: Vascular disruption; Axonal shearing ●Secondary injury: Microglial and astrocyte activation; Neuroinflammatory response; Neurofilament dephosphorylation; progressive expansion of axonal damage ●Secondary injury: Microglial and astrocyte activation; Neuroinflammatory response; Neurofilament dephosphorylation; progressive expansion of axonal damage ●Mechanically compliant stretchable hydrogels ●Mechanically compliant stretchable hydrogels ●Neuroprotective antioxidant nanocarriers ●Neuroprotective antioxidant nanocarriers ●Flexible low-modulus aligned scaffolds ●Flexible low-modulus aligned scaffolds ●Myelin-regenerative cell delivery systems ●Myelin-regenerative cell delivery systems ●Injectable dECM microgels ●Injectable dECM microgels ●Neurotrophic factor sustained-release systems ●Neurotrophic factor sustained-release systems [[65], [66], [67], [68]] [[65], [66], [67], [68]] Contusion Contusion models, which simulate the most prevalent clinical etiologies of TSCI, such as traffic accidents and falls, are generally more clinically relevant to TSCI [73]. They faithfully mirror the patient-specific pathological cascade, spanning initial mechanical trauma, secondary neuroinflammation, edema, and glial scarring. In terms of therapeutic translation, spinal cord contusion lesions are characterized by a heterogeneous microenvironment and the presence of residual neural tissue [74]. Therefore, this type of model is particularly well-suited for evaluating minimally invasive biomaterial platforms, including injectable hydrogels, nanoparticle systems, microstructured scaffolds, and conductive composite materials [75]. These strategies excel at filling cavities, modulating inflammation, guiding axon growth, and enabling minimally invasive delivery without disrupting residual neural tissue. Compared with other animal models, partial tissue continuity and residual neural pathways remain intact; in contusion models, there is a risk of overstating the efficacy of biomaterial systems that rely on surrounding host tissues for integration. Conversely, they often underestimate the immense challenge of reversing extensive axonal disruption seen in severe clinical scenarios. Crush Similarly, crush models excel at mimicking clinical compressive TSCI resulting from spinal fractures, dislocations, tumor mass effects, or cervical spondylosis, rendering them highly relevant to acute compression and chronic myelopathy. Pathologically, crush models are defined by sustained ischemia, inflammation, and preserved tissue continuity. Compared to the transection, a crush injury does not result in extensive tissue defects, making it more suitable for evaluating flexible conformal materials. Ideal strategies include injectable adhesive hydrogels, minimally invasive sustained-release systems, mechanically compliant flexible scaffolds, and injectable ECM materials. These biomaterials can integrate tightly with compressed host tissue, relieve secondary compression, promote microcirculation, and accelerate functional rehabilitation while avoiding additional mechanical insults. Nevertheless, given the tightly regulated compression intensity and duration characteristic of laboratory settings, crush models may overstate the therapeutic performance of anti-compression and anti-fibrotic materials, while failing to fully capture the complexity of clinical delayed decompression or repeated mechanical insults. Transection In contrast, transection models involve complete interruption of neural pathways and the formation of a tissue gap. These paradigms, which simulate the total severance of neural structures induced by catastrophic trauma or surgical resection, are widely deployed to evaluate the bridging and scaffolding efficacy of advanced biomaterials, such as highly oriented conduits and spinal cord organoids. Unlike the crush, contusion, and traction models that preserve nerve fascicles, the transection model lacks residual neural tissue, resulting in a significant deviation from clinical pathology. Owing to the absolute loss of tissue continuity and the total absence of residual neural tracts, these models can inherently overstate the regenerative potential of specific scaffold- and organoid-based interventions. In clinical practice, the presence of scarred residual tissue and a highly inhibitory microenvironmental niche renders functional circuit reconstruction far more formidable than within the idealized anatomical gaps characteristic of animal models. Therefore, regenerative data obtained from transection models should be cautiously translated to clinical settings where anatomical continuity is typically partially retained. Traction Traction models offer high translational fidelity for clinical distraction injuries involving axial tensile stress, such as those arising from spinal fracture-dislocation, spinal cord tethering, or intraoperative over-traction. Pathologically, traction injuries manifest as diffuse axonal stretching, demyelination, and microvascular disruption, notably occurring without prominent cavitation. This specific phenotype mandates the use of mechanically resilient yet biocompatible engineering systems, including compliant hydrogels, neuroprotective nanomedicines, flexible, low-modulus scaffolds, and myelin-supportive, cell-laden constructs. These platforms can resist secondary traction forces, protect vulnerable axons, promote remyelination, and attenuate delayed degeneration. However, compared to other models, the traction injury does not create a tissue cavity, which may underestimate the efficacy of rigid bridging scaffolds that rely on filling discrete gaps, while overestimating the effectiveness of pure neuroprotective or anti-inflammatory strategies in clinical cases involving complex tissue damage. Species selection Among the animal models used in TSCI research, rodents remain the predominant species, accounting for 88.4% of published studies, with rats comprising 72.4% and mice 16% (Fig. 3) [76]. Rodent animal models are inexpensive and easy to use, making them widely employed to investigate fundamental biological mechanisms. Nevertheless, interspecies differences in anatomical structure, mechanical properties, and neural function pose a major barrier to translating laboratory findings on biomaterials into clinical therapies. When matching mechanical properties, rat spinal cord tissue is approximately twice as stiff as mouse spinal cord tissue [77]. Indentation testing shows that rat spinal cord tissue has an elastic modulus of 1.3 kPa, whereas human spinal cord tissue has an elastic modulus of 1.4 MPa, creating an enormous gap between the two values [78]. Hydrogel repair materials rely heavily on mechanical compatibility with native spinal tissue to achieve safe material delivery, low-trauma implantation, and effective anti-inflammatory effects. Large mechanical mismatches across different animal species may cause secondary tissue damage during surgery and exacerbate local inflammatory responses. Favorable outcomes observed in rodent trials, therefore, often fail to replicate in human clinical practice. This significantly limits the reliability of extrapolating animal experimental data to human patients. In contrast, large animal models, such as pigs, dogs, and non-human primates, exhibit greater anatomical and physiological similarity to humans, thereby offering superior translational relevance for the validation of complex tissue-engineering grafts [79]. Therefore, it is necessary to conduct small-scale experiments in non-human primates before clinical trials, especially to assess the effectiveness and safety of tissue-engineering grafts. Beyond mammalian models, non-mammalian species endowed with unique epimorphic regenerative capacities, such as salamanders and geckos, serve as invaluable mechanistic platforms in spinal cord regeneration research.Fig. 3Species of animals used in 2209 animal model studies of SCI [76].Fig. 4Therapeutic strategies for TSCI. Therapeutic strategies for TSCI include gene therapy (mTOR, PTEN, KCC2 modulation), cell therapy (stem cells, Schwann cells, olfactory ensheathing cells), drug and factor delivery (methylprednisolone, BDNF, NT-3), physiotherapeutic interventions (electrical stimulation, brain–computer interfaces), and tissue-engineering platforms (SCOs, hydrogels, scaffolds, nanoparticles). Species of animals used in 2209 animal model studies of SCI [76]. Therapeutic strategies for TSCI. Therapeutic strategies for TSCI include gene therapy (mTOR, PTEN, KCC2 modulation), cell therapy (stem cells, Schwann cells, olfactory ensheathing cells), drug and factor delivery (methylprednisolone, BDNF, NT-3), physiotherapeutic interventions (electrical stimulation, brain–computer interfaces), and tissue-engineering platforms (SCOs, hydrogels, scaffolds, nanoparticles). Selection of the timing of outcome assessment The timing of terminal outcome assessments varies across TSCI animal models, depending on lesion pathology progression and inherent spontaneous recovery capacity. Most rodent experiments set 8 weeks as the terminal time point for detection [28]. By this stage, lesion-induced tissue remodeling and hindlimb motor function both reach stable plateaus in rats and mice. Large animal models, including canines and non-human primates, require observation periods of 12 weeks or longer [80]. Their elaborate corticospinal circuitry more closely resembles that of the human nervous system, resulting in slower neural regeneration after trauma. Neurological grading in canine TSCI models can also be matched to human ASIA impairment scales at corresponding postoperative time points [81]. Apart from terminal endpoint testing, researchers conduct regular short-term behavioral tracking and staged histological sampling covering acute, subacute, and chronic injury phases. Pathological phase shifts proceed rapidly in rodent lesions. Immune and glial responses post-SCI vary greatly across species, with distinct patterns of immune infiltration, cystic cavity formation, and astrocyte activation among rodents, primates, and humans [82]. Overall, researchers must fully account for interspecies variation when designing assessment timelines. Properly selected observation windows allow accurate evaluation of the translational potential of repair interventions. Therapeutic strategies for TSCI Clinically, management strategies for TSCI rely on prompt surgical decompression, spinal stabilization, intensive glucocorticoid pulse therapy (such as methylprednisolone), and systematic rehabilitation training. Nevertheless, clinical data reveal that although glucocorticoid administration offers marginal neuroprotection, it introduces profound risks of systemic infection and gastrointestinal bleeding, leaving the therapeutic utility of these interventions heavily debated [83,84]. Consequently, the development of safer, more effective TSCI repair strategies represents an urgent clinical imperative. Driven by this need, a multitude of experimental therapeutic approaches have been actively explored over the past decade, including cell therapy, drug/factor therapy, gene therapy, and physiotherapeutic interventions (Fig. 4). A concise comparison of these strategies relative to tissue engineering is provided in Table 2. In brief, while cell therapy, drug/factor therapy, gene therapy, and physiotherapeutic interventions have demonstrated encouraging yet modest efficacy in preclinical TSCI models, their clinical translation remains severely bottlenecked. Cell transplantation aims to replace lost neural cells, but it faces extremely low survival rates and inadequate retention within the hyper-inflammatory lesion site. Drug and factor therapies can suppress secondary injury, yet they are undermined by poor stability, short half-lives, and rapid systemic clearance, which preclude sustained localized retention. Gene therapy enables targeted regulation of regenerative pathways but remains constrained by low delivery efficiency and unclear long-term safety in clinical TSCI scenarios. Meanwhile, physiotherapeutic interventions, including electrical stimulation and brain-computer interfaces, support functional rehabilitation but cannot reconstruct structural defects or reverse the inhibitory scar microenvironment inherent to TSCI. Collectively, these strategies act on individual pathological aspects but fail to comprehensively resolve the structural, cellular, and microenvironmental disorders caused by TSCI.Table 2Comparison of therapeutic strategies for TSCI.Table 2TherapeuticStrategiesAdvantagesDisadvantagesRef.Cell Therapy●Can supplement damaged neural cells●Potential for differentiation into functional neurons/glia●Poor survival and retention of transplanted cells●Vulnerable to an acute inflammatory microenvironment[[85], [86], [87], [88]]Drug/FactorsTherapy●Directly targets the lesion microenvironment●Simple administration●Low immunogenicity●Poor stability●Short half-life●Rapid systemic clearance●Low local bioavailability[[89], [90], [91], [92]]Gene Therapy●Precise modulation of molecular targets●Long-term therapeutic effect●Unproven long-term safety●Low delivery efficiency●High technical threshold●Predominantly preclinical[[93], [94], [95], [96], [97], [98], [99], [100], [101]]Physiotherapeutic Interventions●Non-invasive●High safety●Easy clinical application●Adjuvant effect on rehabilitation●Cannot address structural defects●Fails to remodel the inhibitory microenvironment●Only plays an adjuvant role[75,[102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112]]TissueEngineering●Integrates advantages of other●Provides structural support●Precise delivery●Microenvironmental remodeling●Tailored for TSCI complexity●Complex preparation process●High cost●Technical bottlenecks in clinical transformation (e.g., biocompatibility, safety) Table 2Comparison of therapeutic strategies for TSCI.Table 2TherapeuticStrategiesAdvantagesDisadvantagesRef.Cell Therapy●Can supplement damaged neural cells●Potential for differentiation into functional neurons/glia●Poor survival and retention of transplanted cells●Vulnerable to an acute inflammatory microenvironment[[85], [86], [87], [88]]Drug/FactorsTherapy●Directly targets the lesion microenvironment●Simple administration●Low immunogenicity●Poor stability●Short half-life●Rapid systemic clearance●Low local bioavailability[[89], [90], [91], [92]]Gene Therapy●Precise modulation of molecular targets●Long-term therapeutic effect●Unproven long-term safety●Low delivery efficiency●High technical threshold●Predominantly preclinical[[93], [94], [95], [96], [97], [98], [99], [100], [101]]Physiotherapeutic Interventions●Non-invasive●High safety●Easy clinical application●Adjuvant effect on rehabilitation●Cannot address structural defects●Fails to remodel the inhibitory microenvironment●Only plays an adjuvant role[75,[102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112]]TissueEngineering●Integrates advantages of other●Provides structural support●Precise delivery●Microenvironmental remodeling●Tailored for TSCI complexity●Complex preparation process●High cost●Technical bottlenecks in clinical transformation (e.g., biocompatibility, safety) Comparison of therapeutic strategies for TSCI. ●Can supplement damaged neural cells ●Can supplement damaged neural cells ●Potential for differentiation into functional neurons/glia ●Potential for differentiation into functional neurons/glia ●Poor survival and retention of transplanted cells ●Poor survival and retention of transplanted cells ●Vulnerable to an acute inflammatory microenvironment ●Vulnerable to an acute inflammatory microenvironment [[85], [86], [87], [88]] [[85], [86], [87], [88]] ●Directly targets the lesion microenvironment ●Directly targets the lesion microenvironment ●Simple administration ●Simple administration ●Low immunogenicity ●Low immunogenicity ●Poor stability ●Poor stability ●Short half-life ●Short half-life ●Rapid systemic clearance ●Rapid systemic clearance ●Low local bioavailability ●Low local bioavailability [[89], [90], [91], [92]] [[89], [90], [91], [92]] ●Precise modulation of molecular targets ●Precise modulation of molecular targets ●Long-term therapeutic effect ●Long-term therapeutic effect ●Unproven long-term safety ●Unproven long-term safety ●Low delivery efficiency ●Low delivery efficiency ●High technical threshold ●High technical threshold ●Predominantly preclinical ●Predominantly preclinical [[93], [94], [95], [96], [97], [98], [99], [100], [101]] [[93], [94], [95], [96], [97], [98], [99], [100], [101]] ●Non-invasive ●Non-invasive ●High safety ●High safety ●Easy clinical application ●Easy clinical application ●Adjuvant effect on rehabilitation ●Adjuvant effect on rehabilitation ●Cannot address structural defects ●Cannot address structural defects ●Fails to remodel the inhibitory microenvironment ●Fails to remodel the inhibitory microenvironment ●Only plays an adjuvant role ●Only plays an adjuvant role [75,[102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112]] [75,[102], [103], [104], [105], [106], [107], [108], [109], [110], [111], [112]] ●Integrates advantages of other ●Integrates advantages of other ●Provides structural support ●Provides structural support ●Precise delivery ●Precise delivery ●Microenvironmental remodeling ●Microenvironmental remodeling ●Tailored for TSCI complexity ●Tailored for TSCI complexity ●Complex preparation process ●Complex preparation process ●High cost ●High cost ●Technical bottlenecks in clinical transformation (e.g., biocompatibility, safety) ●Technical bottlenecks in clinical transformation (e.g., biocompatibility, safety) In the field of TSCI repair, by contrast, tissue engineering has emerged as the most promising interdisciplinary approach to break through long-standing clinical bottlenecks, precisely because it targets the core pathological features that define TSCI. TSCI is distinguished by simultaneous tissue loss, cavity formation, glial scar barrier formation, vascular disruption, and a chronically inhibitory microenvironment, which collectively pose challenges that individual conventional therapies fail to resolve. Through the synergistic integration of biomimetic scaffolds, functional hydrogels, targeted delivery systems, and cell-based constructs, tissue engineering enables a customizable, multi-faceted intervention that directly matches the heterogeneous, evolving pathology of TSCI. Crucially, tissue engineering provides structural bridging and mechanical support to fill cystic cavities, direct oriented axonal regeneration across lesion gaps, and restore neural tissue continuity, achieving an outcome unmatched by cell, drug, or physical monotherapies alone [113,114]. Concurrently, it serves as a localized delivery platform for cells, neurotrophic factors, anti-inflammatory molecules, and gene regulators, thereby achieving sustained, site-specific modulation of the hostile TSCI microenvironment while avoiding systemic side effects [[115], [116], [117]]. Furthermore, it constructs biomimetic microenvironments that mimic the native spinal cord extracellular matrix, reduce glial scarring, promote angiogenesis, and convert inhibitory signals into pro-regenerative cues, ultimately reversing the pathological cascades unique to TSCI [118]. In contrast to monotherapies, tissue engineering integrates the strengths of cell therapy, drug delivery, gene regulation, and physical stimulation while overcoming their individual limitations [119]. This integrative and structurally supportive capacity renders tissue engineering irreplaceable for TSCI repair, standing as the definitive paradigm capable of concurrently reversing macrostructural damage and microenvironmental dysfunction. Accordingly, the subsequent sections of this review systematically delineate tissue engineering strategies specifically engineered for TSCI, including biomaterial design, functionalized repair systems, translational progress, and remaining clinical challenges. By analyzing material optimization, multimodal integration, and translational barriers, we aim to provide a comprehensive reference for advancing TSCI repair toward clinical application.5.Classes and Properties of Biomaterials for TSCI Repair 5.Classes and Properties of Biomaterials for TSCI Repair Classes and Properties of Biomaterials for TSCI Repair Biomaterials play an irreplaceable role in TSCI repair, as their structural and mechanical properties directly determine cellular behaviors, immune responses, glial scar formation, axonal extension, and functional recovery. To maximize therapeutic success, a rational material design must define clear structure–property–function relationships that align with the distinct pathological profiles of acute and chronic TSCI [120]. Acute TSCI, dominated by inflammatory edema, cell death, and tissue friability, requires compliant, soft, and anti-inflammatory hydrogels to avoid further mechanical trauma. In contrast, chronic TSCI features cystic cavitation, glial scar barriers, and interrupted neural tracts, demanding structurally anisotropic, mechanically supportive scaffolds capable of guiding long-distance axon regeneration. The subsequent sections systematically dissect how natural polymers, synthetic/semi-synthetic substrates, and multifunctional biomaterials meet these time-dependent pathological demands through programmable stiffness, directional topography, controllable degradation kinetics, and customized bioactive modifications, with an in-depth discussion of mechanical regulatory mechanisms and clinical-translational bottlenecks in Section 5.5. Natural biomaterials Natural biomaterials, primarily derived from natural biopolymers, possess remarkable advantages, including excellent biodegradability, favorable biocompatibility, and low immunogenicity. These properties meet the core requirements of biomaterials for effective TSCI repair. Beyond these general characteristics, the unique structures and properties of various natural biomaterials, such as elasticity, porosity, degradation rates, and release kinetics, directly influence their performance in regulating cell behavior, immune responses, glial scar formation, axonal elongation, and functional repair following TSCI. Furthermore, these versatile attributes make natural polymers exceptional carriers for drugs, growth factors, and cellular therapies, enabling synergistic effects that support neural regeneration and functional recovery (Table 3) [133].Table 3The natural biomaterials for TSCI repair.Table 3Natural biomaterialKey propertiesMechanical propertiesSuitable TSCI phaseApplicationSafety considerationsRef.Extracellular matrix●Rapid biodegradation;●Good biocompatibility;●Provide a 3D structure similar to that of real tissue;●Containing bioactive factors●Good viscoelasticityAcute; Chronic●Axonal guidance;●Immune regulation;●Cell/factor delivery;●Large batch differences;●Insufficient mechanical strength[121]Collagen●Tunable degradation rate;●Regulatable crosslinking density;●Good cell adhesive properties●Adjustable physical and chemical properties;●Enzymatic degradation (collagenase Ⅰ Ⅱ)Acute; Chronic●Injectable scaffolds;●Drug sustained-release;●Cell carriers;●Directional axon guidance●Poor mechanical stability[122]Hyaluronic Acid●Good biocompatibility;●High water content (80-95%)●Low stiffness;●High viscoelasticityAcute●Targeted delivery;●Cell encapsulation●Limited mechanical strength;●Fast dissolving[[123], [124], [125]]Fibrin●Biocompatibility;●Modifiability●Adjustable physical and chemical propertiesAcute●Support axonal regrowth;●Carry cells and therapeutic factors●Rapid degradation rate;●Weak mechanical properties[126]Keratin●Complex component●Medium stiffnessAcute●Inflammation regulation●Component heterogeneity;●Lack of directional guidance ability[127,128]Alginate●Good biocompatibility;●Regulatable crosslinking density●Adjustable physical and chemical propertiesAcute●Sustained drug release;●Cell encapsulation●Lacks intrinsic cell adhesion●High viscosity[129]Chitosan●Good biocompatibility;●Antimicrobial;●Chemically modifiable●Adjustable physical and chemical propertiesAcute; Chronic●Drug delivery;●Conductive scaffolds (modified);●Tissue adhesion●Limited solubility at physiological[130]Silk fibroin●Strong mechanical properties;●Good biocompatible●Large break strain (4–26%);●Ultimate strength (300–740 MPa);●Toughness (70–78 MJ m−3)Acute; Chronic●Scaffolding●Slow degradation●Chemical modification required[131,132] Table 3The natural biomaterials for TSCI repair.Table 3Natural biomaterialKey propertiesMechanical propertiesSuitable TSCI phaseApplicationSafety considerationsRef.Extracellular matrix●Rapid biodegradation;●Good biocompatibility;●Provide a 3D structure similar to that of real tissue;●Containing bioactive factors●Good viscoelasticityAcute; Chronic●Axonal guidance;●Immune regulation;●Cell/factor delivery;●Large batch differences;●Insufficient mechanical strength[121]Collagen●Tunable degradation rate;●Regulatable crosslinking density;●Good cell adhesive properties●Adjustable physical and chemical properties;●Enzymatic degradation (collagenase Ⅰ Ⅱ)Acute; Chronic●Injectable scaffolds;●Drug sustained-release;●Cell carriers;●Directional axon guidance●Poor mechanical stability[122]Hyaluronic Acid●Good biocompatibility;●High water content (80-95%)●Low stiffness;●High viscoelasticityAcute●Targeted delivery;●Cell encapsulation●Limited mechanical strength;●Fast dissolving[[123], [124], [125]]Fibrin●Biocompatibility;●Modifiability●Adjustable physical and chemical propertiesAcute●Support axonal regrowth;●Carry cells and therapeutic factors●Rapid degradation rate;●Weak mechanical properties[126]Keratin●Complex component●Medium stiffnessAcute●Inflammation regulation●Component heterogeneity;●Lack of directional guidance ability[127,128]Alginate●Good biocompatibility;●Regulatable crosslinking density●Adjustable physical and chemical propertiesAcute●Sustained drug release;●Cell encapsulation●Lacks intrinsic cell adhesion●High viscosity[129]Chitosan●Good biocompatibility;●Antimicrobial;●Chemically modifiable●Adjustable physical and chemical propertiesAcute; Chronic●Drug delivery;●Conductive scaffolds (modified);●Tissue adhesion●Limited solubility at physiological[130]Silk fibroin●Strong mechanical properties;●Good biocompatible●Large break strain (4–26%);●Ultimate strength (300–740 MPa);●Toughness (70–78 MJ m−3)Acute; Chronic●Scaffolding●Slow degradation●Chemical modification required[131,132] The natural biomaterials for TSCI repair. ●Rapid biodegradation; ●Rapid biodegradation; ●Good biocompatibility; ●Good biocompatibility; ●Provide a 3D structure similar to that of real tissue; ●Provide a 3D structure similar to that of real tissue; ●Containing bioactive factors ●Containing bioactive factors ●Good viscoelasticity ●Good viscoelasticity ●Axonal guidance; ●Axonal guidance; ●Immune regulation; ●Immune regulation; ●Cell/factor delivery; ●Cell/factor delivery; ●Large batch differences; ●Large batch differences; ●Insufficient mechanical strength ●Insufficient mechanical strength [121] [121] ●Tunable degradation rate; ●Tunable degradation rate; ●Regulatable crosslinking density; ●Regulatable crosslinking density; ●Good cell adhesive properties ●Good cell adhesive properties ●Adjustable physical and chemical properties; ●Adjustable physical and chemical properties; ●Enzymatic degradation (collagenase Ⅰ Ⅱ) ●Enzymatic degradation (collagenase Ⅰ Ⅱ) ●Injectable scaffolds; ●Injectable scaffolds; ●Drug sustained-release; ●Drug sustained-release; ●Cell carriers; ●Cell carriers; ●Directional axon guidance ●Directional axon guidance ●Poor mechanical stability ●Poor mechanical stability [122] [122] ●Good biocompatibility; ●Good biocompatibility; ●High water content (80-95%) ●High water content (80-95%) ●Low stiffness; ●Low stiffness; ●High viscoelasticity ●High viscoelasticity ●Targeted delivery; ●Targeted delivery; ●Cell encapsulation ●Cell encapsulation ●Limited mechanical strength; ●Limited mechanical strength; ●Fast dissolving ●Fast dissolving [[123], [124], [125]] [[123], [124], [125]] ●Biocompatibility; ●Biocompatibility; ●Modifiability ●Modifiability ●Adjustable physical and chemical properties ●Adjustable physical and chemical properties ●Support axonal regrowth; ●Support axonal regrowth; ●Carry cells and therapeutic factors ●Carry cells and therapeutic factors ●Rapid degradation rate; ●Rapid degradation rate; ●Weak mechanical properties ●Weak mechanical properties [126] [126] ●Complex component ●Complex component ●Medium stiffness ●Medium stiffness ●Inflammation regulation ●Inflammation regulation ●Component heterogeneity; ●Component heterogeneity; ●Lack of directional guidance ability ●Lack of directional guidance ability [127,128] [127,128] ●Good biocompatibility; ●Good biocompatibility; ●Regulatable crosslinking density ●Regulatable crosslinking density ●Adjustable physical and chemical properties ●Adjustable physical and chemical properties ●Sustained drug release; ●Sustained drug release; ●Cell encapsulation ●Cell encapsulation ●Lacks intrinsic cell adhesion ●Lacks intrinsic cell adhesion ●High viscosity ●High viscosity [129] [129] ●Good biocompatibility; ●Good biocompatibility; ●Antimicrobial; ●Antimicrobial; ●Chemically modifiable ●Chemically modifiable ●Adjustable physical and chemical properties ●Adjustable physical and chemical properties ●Drug delivery; ●Drug delivery; ●Conductive scaffolds (modified); ●Conductive scaffolds (modified); ●Tissue adhesion ●Tissue adhesion ●Limited solubility at physiological ●Limited solubility at physiological [130] [130] ●Strong mechanical properties; ●Strong mechanical properties; ●Good biocompatible ●Good biocompatible ●Large break strain (4–26%); ●Large break strain (4–26%); ●Ultimate strength (300–740 MPa); ●Ultimate strength (300–740 MPa); ●Toughness (70–78 MJ m−3) ●Toughness (70–78 MJ m−3) ●Scaffolding ●Scaffolding ●Slow degradation ●Slow degradation ●Chemical modification required ●Chemical modification required [131,132] [131,132] Extracellular matrix The extracellular matrix (ECM) comprises an intricate assembly of proteoglycans, bioactive molecules, and structural proteins. Its tissue-matched viscoelasticity and moderate stiffness minimize mechanotransduction-triggered overactivation of microglia and the secretion of pro-inflammatory cytokines. This, in turn, breaks the positive feedback loop of chronic astrogliosis, which is particularly crucial for preventing exacerbated glial scarring in both acute and chronic TSCI [134,135]. Furthermore, the porous, nanofibrous architecture promotes cell infiltration and vascularization, while preserving endogenous bioactive factors, thereby reprogramming local immune cells toward anti-inflammatory, pro-regenerative M2-like phenotypes to restrain scar precursor cell aggregation [121]. Such structural and mechanical characteristics render ECM well-suited for chronic TSCI, where it can remodel the inhibitory niche rather than serve as a passive cavity filler. Owing to these mild mechanics and bioactive compositions, ECM supports both factor delivery and axonal extension [[136], [137], [138]]. However, its insufficient mechanical strength and batch variability limit its ability to bridge large tissue gaps. This limits its independent application in severe transection-type TSCI, which requires long-term mechanical support for axonal traversal, a core bottleneck that hinders its therapeutic translation. Collagen Collagen, the most abundant structural protein in mammalian tissues, undergoes precise enzymatic degradation in vivo. It contains abundant amino and carboxyl groups, enabling facile functionalization for tissue repair and regeneration [139,140]. Low-modulus collagen formulations effectively mitigate mechanical compression, making them well-suited for acute TSCI to alleviate inflammatory exacerbation; conversely, their oriented fibrous structures deliver clear anisotropic topographic cues that direct ordered axonal guidance across chronic cavitated lesions [141]. However, collagen carries risks of immunogenicity and pathogen transmission. Consequently, researchers have derived gelatin from collagen, which has significantly diminished antigenicity, superior biocompatibility, and an equivalent capacity to promote cell adhesion and proliferation [142,143]. The controllable degradation kinetics of these collagenous matrices enable the synchronized release of bioactive factors, making them ideal for localized delivery systems [[144], [145], [146]]. Their robust cell-adhesion properties and adjustable porosity promote neural cell infiltration and axonal outgrowth. Despite these advantages, insufficient mechanical stability limits standalone use in TSCI cases that require long-term structural support, highlighting a key limitation for gap-bridging applications. Hyaluronic acid Hyaluronic acid (HA) is a multifunctional glycosaminoglycan widely distributed in connective, epithelial, and neural tissues [147]. Exhibiting exceptionally low stiffness, high water content, and prominent viscoelasticity, HA closely recapitulates the ultra-soft mechanical environment of the native uninjured spinal cord. This near-native mechanical matching inhibits mechanosensitive ion channel activation in microglia and astrocytes, thereby suppressing microglial pro-inflammatory polarization and excessive astrogliosis, making HA uniquely suitable for mitigating the immune storm during the acute inflammatory phase of TSCI [[148], [149], [150], [151]]. Furthermore, its hydrated network cushions fragile, edematous tissues against mechanical trauma while serving as an efficient vehicle for localized factor delivery and cell encapsulation [152]. Nevertheless, HA is limited by poor mechanical strength and rapid dissolution, thereby confining its utility primarily to anti-inflammatory support and delivery platforms. Fibrin Fibrin is formed via fibrinogen–thrombin crosslinking and is widely used in clinical settings [126]. It exhibits excellent biocompatibility, versatile chemical modifiability, and tunable mechanical kinetics tailored to the acute phases of TSCI. Fibrin synchronizes its degradation with active tissue healing and integrates rapidly with surrounding host tissues [118]. These rapid gelation kinetics allow for precise, conformal adaptation to irregular lesion cavities, while its biodegradable profile matches early tissue remodeling. Crucially, its compliant mechanics reduce secondary damage and support cell survival under inflammatory stress [153]. Consequently, fibrin has become a preferred vehicle for the localized delivery of cells, exosomes, and growth factors in acute TSCI paradigms [154]. Nevertheless, its rapid degradation rate and poor mechanical stability preclude sustained structural support, limiting its utility in bridging large chronic gaps. Keratin Keratin exhibits moderate mechanical stiffness and immunomodulatory activity, rendering it well-poised to modulate early hyperinflammatory responses [127,155]. Its porous structure provides physical support while avoiding excessive fibrotic scarring [127]. However, its heterogeneous protein composition and lack of aligned anisotropic topological cues fail to activate directional neurite outgrowth signaling, thereby eliminating its capacity to guide ordered long-distance axon extension across lesion cavities and confining its primary therapeutic function to acute immunomodulation rather than chronic structural neural repair [156]. The undefined composition also complicates mechanistic interpretation, representing a critical bottleneck for the standardization and reproducible manufacturing of keratin-based TSCI repair platforms. Alginate Alginate is a polysaccharide extracted from brown algae and certain bacteria, with good biocompatibility, tunable degradation, mechanical stability, injectability, and three-dimensional processability [157,158]. Its highly adjustable crosslinking networks provide tailored mechanical profiles, making it suitable for sustained drug release and cell encapsulation in acute TSCI [159]. It exerts antioxidant effects against oxidative stress and promotes neural cell proliferation [160,161]. In TSCI repair, alginate hydrogels inhibit fibrotic scar formation, improve functional recovery, and partially restore electrophysiological conduction [162,163]. However, alginate inherently lacks endogenous cell-adhesive motifs and exhibits an elevated macromolecular viscosity, which collectively constrain its broader application in complex tissue-engineered constructs [120]. Chitosan Chitosan, a partially deacetylated derivative derived from crustacean exoskeletons, exhibits exceptional biodegradability and electrical conductivity, making it a widely used functional carrier in neural tissue engineering [164]. Owing to their superior biocompatibility, inherent antimicrobial activity, and tailored functionalization options, chitosan hydrogels are versatile enough to address both acute and chronic TSCI. Soft formulations conform to injured tissue and reduce inflammatory activation during the acute phase, whereas modified conductive constructs enhance electrical signaling and neurite growth in chronic TSCI [[165], [166], [167], [168]]. Targeted chemical modifications can further enhance its biocompatibility, bioactivity, and degradation kinetics to match endogenous tissue healing [169]. However, its limited physiological solubility at the neutral pH of the spinal cord and relatively slow degradation rates lead to a discrepancy with stage-specific tissue remodeling. Undegraded residual chitosan can trigger delayed foreign-body immune responses and physically impede axonal ingrowth in later stages, thereby hindering timely host tissue remodeling and synchronized functional neural regeneration. Silk fibroin Characterized by exceptional tensile strength, toughness, and long-term stability, silk fibroin (SF) is uniquely qualified to support durable tissue reconstruction in chronic TSCI. Its robust mechanical properties resist physical distortion and provide reliable support for axonal extension across tissue defects [170,171]. However, pure SF lacks intrinsic cell-adhesive domains, limiting its capacity to support neuronal attachment and expansion. Consequently, researchers frequently blend SF with the native ECM or specific peptides to enhance its bioactivity and tissue-engineering efficacy [172]. Yet its protracted degradation rate remains a primary constraint, necessitating rational chemical modification to synchronize material dissolution with endogenous spinal cord regeneration. Synthetic and semi-synthetic biomaterials Synthetic and semi-synthetic biomaterials are formed by polymerizing monomers through physical or chemical cross-linking methods. Unlike natural biopolymers, they offer superior structural reproducibility, tailored functionalization options, and robust mechanical stability [173]. By tailoring stiffness, porosity, anisotropy, and bioactivity, they can be optimized for either modulation of acute inflammation or chronic structural reconstruction. This section introduces typical synthetic and semi-synthetic biomaterials and their application potential in TSCI repair (Table 4).Table 4Synthetic and semi-synthetic biomaterials for TSCI repair.Table 4Natural biomaterialKey propertiesMechanical propertiesSuitable TSCI phaseApplicationSafety considerationsRef.PLGA●Tunable degradation;●Good biocompatibility;●High processability●Adjustable mechanics●Stable structureAcute; Chronic●Drug delivery;●Cell carrier;●Fiber scaffolds●Acidic byproducts;●Hydrophobic;●Low cell affinity[[174], [175], [176], [177]]PLA●High strength;●Good processability;●Biodegradable●High elastic modulus;●Poor tensile strengthChronic●3D printing;●Long-term bridging;●Structural support●Hydrophobic;●Low degradation rate;●Poor cell adhesion[[178], [179], [180], [181]]PGA●Rapid degradation;●Good hydrophilicity;●High porosity●High tensile strength and stiffness;●High melting temperatureAcute●Short-term filling;●Early drug delivery●Too fast degradation;●Low toughness;●Ease of thermal degradation●Lack sufficient mechanical integrity[178,182,183]PCL●Biocompatible;●Bioabsorbable;●Biodegradable●High drug permeability●Low modulus;●Good fatigue resistanceChronic●Electrospun fibers;●Axon guidance;●Long-term support●Hydrophobic;●Slow degradation;●Low bioactivity[178,184]PEG●High hydrophilicity;●Biodegradable●Good biocompatibility●Low immunogenicity●Soft;●Viscoelastic;●High water contentAcute●Injectable hydrogels;●Cell encapsulation;●Drug release●Lack bioactive sites;●No guidance;●Weak structure[185,186] Table 4Synthetic and semi-synthetic biomaterials for TSCI repair.Table 4Natural biomaterialKey propertiesMechanical propertiesSuitable TSCI phaseApplicationSafety considerationsRef.PLGA●Tunable degradation;●Good biocompatibility;●High processability●Adjustable mechanics●Stable structureAcute; Chronic●Drug delivery;●Cell carrier;●Fiber scaffolds●Acidic byproducts;●Hydrophobic;●Low cell affinity[[174], [175], [176], [177]]PLA●High strength;●Good processability;●Biodegradable●High elastic modulus;●Poor tensile strengthChronic●3D printing;●Long-term bridging;●Structural support●Hydrophobic;●Low degradation rate;●Poor cell adhesion[[178], [179], [180], [181]]PGA●Rapid degradation;●Good hydrophilicity;●High porosity●High tensile strength and stiffness;●High melting temperatureAcute●Short-term filling;●Early drug delivery●Too fast degradation;●Low toughness;●Ease of thermal degradation●Lack sufficient mechanical integrity[178,182,183]PCL●Biocompatible;●Bioabsorbable;●Biodegradable●High drug permeability●Low modulus;●Good fatigue resistanceChronic●Electrospun fibers;●Axon guidance;●Long-term support●Hydrophobic;●Slow degradation;●Low bioactivity[178,184]PEG●High hydrophilicity;●Biodegradable●Good biocompatibility●Low immunogenicity●Soft;●Viscoelastic;●High water contentAcute●Injectable hydrogels;●Cell encapsulation;●Drug release●Lack bioactive sites;●No guidance;●Weak structure[185,186] Synthetic and semi-synthetic biomaterials for TSCI repair. ●Tunable degradation; ●Tunable degradation; ●Good biocompatibility; ●Good biocompatibility; ●High processability ●High processability ●Adjustable mechanics ●Adjustable mechanics ●Stable structure ●Stable structure Acute; Chronic Acute; Chronic ●Drug delivery; ●Drug delivery; ●Cell carrier; ●Cell carrier; ●Fiber scaffolds ●Fiber scaffolds ●Acidic byproducts; ●Acidic byproducts; ●Hydrophobic; ●Hydrophobic; ●Low cell affinity ●Low cell affinity [[174], [175], [176], [177]] [[174], [175], [176], [177]] ●High strength; ●High strength; ●Good processability; ●Good processability; ●Biodegradable ●Biodegradable ●High elastic modulus; ●High elastic modulus; ●Poor tensile strength ●Poor tensile strength Chronic Chronic ●3D printing; ●3D printing; ●Long-term bridging; ●Long-term bridging; ●Structural support ●Structural support ●Hydrophobic; ●Hydrophobic; ●Low degradation rate; ●Low degradation rate; ●Poor cell adhesion ●Poor cell adhesion [[178], [179], [180], [181]] [[178], [179], [180], [181]] ●Rapid degradation; ●Rapid degradation; ●Good hydrophilicity; ●Good hydrophilicity; ●High porosity ●High porosity ●High tensile strength and stiffness; ●High tensile strength and stiffness; ●High melting temperature ●High melting temperature Acute Acute ●Short-term filling; ●Short-term filling; ●Early drug delivery ●Early drug delivery ●Too fast degradation; ●Too fast degradation; ●Low toughness; ●Low toughness; ●Ease of thermal degradation ●Ease of thermal degradation ●Lack sufficient mechanical integrity ●Lack sufficient mechanical integrity [178,182,183] [178,182,183] ●Biocompatible; ●Biocompatible; ●Bioabsorbable; ●Bioabsorbable; ●Biodegradable ●Biodegradable ●High drug permeability ●High drug permeability ●Low modulus; ●Low modulus; ●Good fatigue resistance ●Good fatigue resistance Chronic Chronic ●Electrospun fibers; ●Electrospun fibers; ●Axon guidance; ●Axon guidance; ●Long-term support ●Long-term support ●Hydrophobic; ●Hydrophobic; ●Slow degradation; ●Slow degradation; ●Low bioactivity ●Low bioactivity [178,184] [178,184] ●High hydrophilicity; ●High hydrophilicity; ●Biodegradable ●Biodegradable ●Good biocompatibility ●Good biocompatibility ●Low immunogenicity ●Low immunogenicity ●Soft; ●Soft; ●Viscoelastic; ●Viscoelastic; ●High water content ●High water content Acute Acute ●Injectable hydrogels; ●Injectable hydrogels; ●Cell encapsulation; ●Cell encapsulation; ●Drug release ●Drug release ●Lack bioactive sites; ●Lack bioactive sites; ●No guidance; ●No guidance; ●Weak structure ●Weak structure [185,186] [185,186] Polylactic acid-glycolic acid copolymer Polylactic acid-glycolic acid copolymer (PLGA) is a widely used biodegradable polyester with mature synthesis and abundant functional groups for modification. PLGA exhibits tunable degradation, favorable biocompatibility, high processability, adjustable mechanical properties, and a stable structure, making it highly versatile for both acute and chronic TSCI. Altering the monomeric ratio of lactic acid to glycolic acid allows researchers to precisely control the hydrolytic degradation rate, thereby enabling sustained and localized drug delivery [187]. However, the release of acidic byproducts during ester bond cleavage, combined with high surface hydrophobicity and low intrinsic cell affinity, limits its standalone performance in TSCI, necessitating targeted surface modifications to enhance favorable cell–material interactions [174,175]. Poly (lactic acid) Poly (lactic acid) (PLA) provides exceptional tensile strength and long-term structural fidelity, making it suitable for chronic TSCI with large tissue defects. Its rigid matrix enables stable, long-term bridging of cystic cavities, whereas its compatibility with 3D bioprinting and electrospinning techniques allows the engineering of aligned, anisotropic topographies that guide directed axon growth. Despite these structural benefits, the high stiffness, hydrophobicity, and sluggish degradation of pure PLA generate a significant mechanical mismatch at the tissue interface. This poor cytocompatibility hampers robust cellular infiltration, limits spinal cord regeneration, and heightens the potential for persistent foreign-body reactions in long-term repair applications [178]. Poly (glycolic acid) (PGA) Poly(glycolic acid) (PGA) features rapid degradation, high porosity, and good hydrophilicity, which meet the short-term requirements of acute TSCI. Its porous structure facilitates nutrient exchange and early cell colonization, supporting short-term cavity filling and acute drug delivery. However, its excessively rapid dissolution rate, insufficient toughness, and poor mechanical integrity preclude long-term structural support, thereby restricting its role to early-stage intervention rather than chronic reconstruction [178,182,183]. Polycaprolactone Polycaprolactone (PCL) represents a biocompatible, bioabsorbable, and highly flexible aliphatic polyester characterized by high drug permeability, a low elastic modulus, and exceptional fatigue resistance. Consequently, it is widely used in neural tissue engineering as a durable, long-term delivery vehicle for various bioactive factors [188]. Due to its robust structural stability, PCL scaffolds are ideal for providing long-term mechanical bridging and guiding directional axon outgrowth in chronic SCI. However, its strong hydrophobicity and lack of cell-binding motifs limit cellular attachment and native bioactivity [189]. In the long run, its slow degradation rates may also hinder tissue remodeling and functional integration. Poly (ethylene glycol) Poly(ethylene glycol) (PEG) is highly hydrophilic, soft, viscoelastic, and low in immunogenicity, making it ideal for acute TSCI [185,190]. Its soft mechanics match spinal tissues to reduce inflammatory activation, while the hydrated network protects cells and facilitates minimally invasive implantation [191]. Research findings indicate that PEG can repair axonal membranes following diverse injuries, making it an optimal option for acute SCI [[192], [193], [194]]. They are widely used for cell encapsulation, drug delivery, and minimally invasive implantation [185]. Nevertheless, pure PEG lacks bioactive sites and topographical guidance cues, which often translate into weak long-term structural persistence and a limited capacity to drive directed, long-distance axonal regeneration in chronic TSCI [195]. Functional materials By integrating specific physical and chemical functionalities into natural or synthetic substrates, functional biomaterials are tailored to target the complex, multi-phase pathological barriers of TSCI. These materials are engineered at both the molecular and structural levels to enhance integration, reduce inflammation, rescue electrical conduction, and facilitate precise lesion interventions. Functional materials primarily include conductive materials, directional-microstructure materials, adhesive materials, injectable materials, and intelligent-response materials, enabling more efficient TSCI repair strategies. Conductive materials Targeted conductive modification enables conventional, biologically inert biomaterials to acquire biomimetic electrical activity, thereby reconstructing the defective bioelectrical microenvironment after TSCI, enhancing neuronal viability, and facilitating neural stem cell differentiation [196]. Such functional modification primarily compensates for the inherent non-conductive defect in pristine substrate materials, enabling engineered biomaterials to serve as bioelectronic bridges that re-establish disrupted neural signal pathways and activate endogenous regenerative programs [197]. In particular, conductive hydrogels achieve bionic mechanical matching and electrical simulation of native spinal cord tissue through structural and electrical modification, effectively restoring electrical signal transmission in damaged neural regions [198,199]. Piezoelectric doping has emerged as a powerful strategy to introduce controllable electrical performance into insulating polymer matrices. To achieve on-demand, non-invasive electrical intervention for TSCI repair, Chen et al. modified pure electrospun PLA nanofibers by incorporating biodegradable piezoelectric KNN nanowires. The introduction of piezoelectric nanomodifiers endows the originally non-conductive PLA scaffold with ultrasound-responsive electroactive characteristics [200]. The constructed 3D multichannel scaffold can generate wireless, controllable electrical signals in response to external ultrasound stimulation. These in situ electrical stimuli further promote neural stem cell differentiation and intra-lesional angiogenesis, thereby facilitating ordered axonal regeneration and neural circuit rewiring, ultimately improving locomotor recovery after injury (Fig. 5a).Fig. 5Repair of TSCI with conductive materials. a, Ultrasound-powered wireless electrical stimulation via a biodegradable 3D piezoelectric scaffold promotes neural regeneration after SCI. b, The TPP-PDA@BTO nanoparticles generate piezoelectric effects under ultrasonic triggering, achieving targeted regulation of mitochondria, promoting neural differentiation of transplanted neural stem cells and local neural circuit integration, and thereby enhancing neural tissue regeneration and motor function recovery. Repair of TSCI with conductive materials. a, Ultrasound-powered wireless electrical stimulation via a biodegradable 3D piezoelectric scaffold promotes neural regeneration after SCI. b, The TPP-PDA@BTO nanoparticles generate piezoelectric effects under ultrasonic triggering, achieving targeted regulation of mitochondria, promoting neural differentiation of transplanted neural stem cells and local neural circuit integration, and thereby enhancing neural tissue regeneration and motor function recovery. Multi-component composite modification offers a powerful route to combine piezoelectric conductivity and bio-targeting functions within advanced, multifunctional electroactive matrices. Liu et al. developed a dual-modification strategy by synthesizing mitochondria-targeted piezoelectric TPP-PDA@BTO nanoparticles and uniformly compounding them with inert, ROS-responsive hydrogel substrates [201]. The incorporation of these functional piezoelectric nanoparticles successfully transforms the non-electroactive hydrogels into ultrasound-responsive electroactive composites. Under external ultrasound stimulation, the resulting bioelectrical signals restore mitochondrial function in neural stem cells, thereby promoting robust neuronal differentiation. Meanwhile, this localized piezoelectric electrical stimulation modulates microglial polarization toward the anti-inflammatory M2 phenotype, accelerates myelinated axon regeneration, and restrains excessive glial scar formation. This multifunctional modification strategy effectively remodels the inhibitory pathological microenvironment, providing a highly favorable environment for neural regeneration (Fig. 5b). Despite the significant progress achieved by conductive modification strategies, electroactive biomaterials continue to face inherent limitations that hinder their clinical translation. Most conductive functions rely on non-degradable inorganic fillers and synthetic conductive polymer modifiers. Long-term in vivo retention of these exogenous modified components inevitably induces chronic immune inflammation and mechanical mismatch with the soft spinal cord tissue, thereby severely impairing the biosafety and long-term repair efficacy of electroactive biomaterial systems [75,202]. Directional microstructured materials After TSCI, newly regenerated axons typically grow randomly, with only a marginal fraction successfully traversing the lesion core to reconnect with distal targets, which greatly limits functional neural circuit reconstruction [203]. A previous study by Günther et al. validated this phenomenon. When BDNF-expressing cells were seeded into alginate scaffolds with continuous linear channels, axons exhibited oriented elongation along these channels. In comparison, axons grew randomly in groups receiving only simple cell suspension transplantation (Fig. 6a) [204]. This finding indicates that directional microstructures provide critical topographic cues that guide ordered axon extension and serve as physical channels for nutrient exchange, making them ideal for bridging large-scale chronic spinal cord defects. Oriented structural modification renders these scaffolds particularly suitable for chronic TSCI. Chronic lesions typically exhibit cystic cavitation and dense glial scarring, which require structural guidance and long-distance bridging to support nerve regeneration. Conversely, the relatively high rigidity and fixed shape of these materials limit their adaptation to the swollen, edematous microenvironment characteristic of acute TSCI, thereby restricting their clinical utility during early-stage interventions. Based on this principle, Ramanujam et al. fabricated a 3D-printed gelatin methacryloyl–polyethylene glycol diacrylate composite hydrogel scaffold with directional microchannels. In a rat TSCI model, this scaffold provided stable unidirectional guidance, allowing regenerating axons to penetrate the lesion core and form functional neural bridges, thereby significantly improving hindlimb motor function (Fig. 6b) [205]. However, directional microstructure systems still face critical limitations. The inherent mechanical mismatch between rigid microstructured scaffolds and soft spinal cord tissue, together with insufficient cell infiltration within densely packed channels, hinders tight integration of the scaffold with host tissue, ultimately limiting long-term therapeutic efficacy.Fig. 6Repair of TSCI with directional microstructure materials. a, The alginate biomaterials with linear channels that are filled with cells expressing the growth-promoting neurotrophin BDNF promote linear axon extension throughout the channels after transplantation to the injured rat spinal cord; b, A hydrogel containing microchannels using a single-layer DLP 3D-printing process was able to bridge the lesion gap from the rostral to the caudal ends as early as 2 weeks and promote long-term functional recovery. Repair of TSCI with directional microstructure materials. a, The alginate biomaterials with linear channels that are filled with cells expressing the growth-promoting neurotrophin BDNF promote linear axon extension throughout the channels after transplantation to the injured rat spinal cord; b, A hydrogel containing microchannels using a single-layer DLP 3D-printing process was able to bridge the lesion gap from the rostral to the caudal ends as early as 2 weeks and promote long-term functional recovery. Adhesive material TSCI often leads to spinal cord tissue rupture and residual lesion gaps that fail to heal spontaneously. Conventional hydrogels lack interfacial adhesion design, resulting in weak interactions with injured nerve stumps. This disrupts structural continuity at the lesion site and significantly reduces the efficiency of neural regeneration. Therefore, rational design of adhesive interfaces to achieve tight integration with damaged nerve tissue remains a key challenge in TSCI treatment. To address this dilemma, researchers have developed in situ photo-crosslinking systems to enhance interfacial adhesion. Under UV or visible light irradiation, these hydrogels rapidly form covalently crosslinked networks, allowing mechanical interlocking and chemical bonding with surrounding wet tissues [206,207]. Liu et al. fabricated an in situ UV-crosslinked silk fibroin hydrogel that strengthens adhesion via topological entanglement at the hydrogel–spinal cord interface. This structure-determined interfacial stability preserves the morphological integrity of injured nerve stumps, provides persistent anchoring sites for neural cell infiltration and axonal outgrowth, and suppresses microglial hyperactivation triggered by scaffold-tissue detachment, thereby ameliorating the inhibitory lesion microenvironment and promoting efficient neural repair (Fig. 7a) [208]. In addition to chemical crosslinking, mechanical matching and biomimetic modification are employed to optimize adhesion. Traditional materials show severe mechanical mismatch with neural tissue, further weakening interface stability. Inspired by mussel adhesion chemistry, Zheng et al. designed a catechol-functionalized hydrogel with tunable modulus, whose mechanical properties match native spinal cord tissue. The dual integration of bioinspired catechol adhesive chemistry and tissue-matched mechanical mechanics enables seamless dynamic integration with host neural tissues: during the acute phase, the adhesive interface stabilizes edematous and fragile injured tissues, restrains microglial pro-inflammatory polarization, and attenuates secondary tissue damage; during the chronic phase, stable interfacial anchoring provides continuous topological and mechanical support for ordered axonal regeneration and tissue remodeling. This dual modification of adhesive chemistry and mechanical properties enables seamless integration, preserves the continuity of injured nerve stumps, and promotes motor function recovery in severe TSCI rats (Fig. 7b) [209]. In summary, high-efficiency interfacial adhesion achieved by material modification is the core principle for designing effective TSCI repair scaffolds. In contrast to conventional inert hydrogels that merely serve as passive cavity fillers, functionally adhesive hydrogels establish robust, stage-specific chemical and mechanical interfacial binding that accommodates acute inflammatory suppression and chronic neural remodeling requirements. Such reliable interfacial integration eliminates immune inflammation and aberrant glial proliferation induced by scaffold-tissue detachment, provides sustained mechanical support and stable growth substrates for axonal reinnervation and neural tissue reconstruction, and thereby ensures durable neural repair and functional recovery [169,210].Fig. 7Repair of TSCI with adhesive materials. a, An in situ formed glycidyl methacrylate silk fibroin/acrylic laminin hydrogel was fabricated for SCI repair. After being triggered by ultraviolet light, the polymer chains rapidly formed a network and interwove with the spinal cord in a topological entanglement, as if sewing the hydrogel and the moist tissue together at the molecular scale. b, The mussel-inspired hydrogel regulates the growth of neural axons after SCI by simultaneously modulating the Piezo1/RhoA/MLC signaling pathway and ensuring the integration of tissues with materials through its outstanding adhesive performance. Repair of TSCI with adhesive materials. a, An in situ formed glycidyl methacrylate silk fibroin/acrylic laminin hydrogel was fabricated for SCI repair. After being triggered by ultraviolet light, the polymer chains rapidly formed a network and interwove with the spinal cord in a topological entanglement, as if sewing the hydrogel and the moist tissue together at the molecular scale. b, The mussel-inspired hydrogel regulates the growth of neural axons after SCI by simultaneously modulating the Piezo1/RhoA/MLC signaling pathway and ensuring the integration of tissues with materials through its outstanding adhesive performance. Injectable materials TSCI typically generates irregular cystic cavities and persistent inhibitory microenvironments that severely impede tissue repair. Injectability is achieved by tailoring the rheological properties and crosslinking dynamics of biomaterials, allowing such systems to precisely fill irregular lesion cavities, form seamless contact with host tissue, and improve interface compatibility [211,212]. The shear-thinning and fast self-recovery properties render injectable materials especially suitable for acute TSCI, as they readily conform to edematous and irregular cavities while minimizing secondary injury [169]. These materials also serve as efficient carriers for drug and cell delivery due to their dynamically tunable network structures, although they lack sufficient structural rigidity for long-distance axon guidance and bridging (Fig. 8a) [213]. Unlike statically crosslinked hydrogels, this dynamic network maintains stable structural integrity in vivo, and its tissue-matched stiffness further optimizes the regenerative microenvironment, promoting axonal remyelination and angiogenesis. Minimally invasive delivery is another key function enabled by injectable material design. By virtue of their flowable precursor state, these materials can be administered via fine-needle penetration, thereby reducing surgical trauma and secondary damage [214]. In contusion or crush injuries with intact dura mater, Luo et al. precisely administered a spermidine-functionalized injectable hydrogel to the lesion using a microloader. The fluid precursor completely infiltrates and fills irregular cystic defects without a dural incision, while subsequent in situ gelation forms a stable therapeutic microenvironment that inhibits NF-κB-mediated neuroinflammation and mitochondrial-dependent neuronal apoptosis, ultimately promoting neural tissue preservation and long-term motor functional recovery in TSCI mice (Fig. 8b) [215]. Overall, injectable performance is realized by engineering reversible, flowable, and in situ curable networks, which grant morphological adaptability and minimally invasive delivery. This rheological modification strategy is effective for both acute edematous injuries and chronic lesions, showing strong clinical potential. However, a central bottleneck is that the soft network design required for injectability inevitably leads to low mechanical stiffness, which cannot provide sufficient long-term support for large chronic cystic cavities, thereby limiting efficacy in severe TSCI.Fig. 8Injectable materials for TSCI repair. a, Schematic diagram of an injectable self-healing ADA hydrogel for SCI repair; b, Luo et al. designed an injectable hydrogel that was precisely injected into the spinal cord contusion site using a microloader. Injectable materials for TSCI repair. a, Schematic diagram of an injectable self-healing ADA hydrogel for SCI repair; b, Luo et al. designed an injectable hydrogel that was precisely injected into the spinal cord contusion site using a microloader. Intelligent responsive materials Intelligent responsiveness is realized by introducing stimulus-sensitive motifs or functional nanoparticles into host biomaterials, enabling the composites to recognize specific internal or external stimuli, including physical fields and biochemical signals. Such a modification provides tailored functions, including controlled drug release, dynamic microenvironment modulation, adaptive tissue support, and directional neural guidance at the lesion site [216]. Based on the design of responsive components, intelligent materials are classified into two categories: physically responsive systems (magnetic, light, ultrasound, thermal) and chemically responsive systems (pH, ROS, enzymes) [217]. By virtue of their stimuli-responsive design, intelligent materials can serve the entire TSCI pathological process, rather than only the acute phase. They sense sequential pathological changes, including an early ROS burst, inflammation, and late glial scarring, enabling spatiotemporal, on-demand regulation to mitigate secondary injury and promote nerve regeneration. Unlike passive biomaterials, intelligent responsive materials integrate controlled release, dynamic modulation, axon guidance, and tissue remodeling through the rational design of responsive moieties, thereby overcoming the limitations of single-function platforms. Physically responsive behavior is achieved by incorporating functional fillers that capture and transduce external energy. A typical example is the magnetically responsive aligned fibrin hydrogel (MAFG) developed by Yang et al., whose magnetic responsiveness is realized by uniformly embedding superparamagnetic Fe3O4 magnetic nanoparticles (MNPs). The MNPs localize and amplify external static magnetic field signals, promoting PC12 cell proliferation, upregulating neurotrophic factor secretion, enhancing axonal regeneration and angiogenesis, and finally improving motor function recovery in TSCI (Fig. 9a) [218]. Chemically responsive systems are constructed by introducing chemically labile bonds or ROS- or enzyme-sensitive segments into the polymer network. These motifs enable endogenous signal-driven structural changes or payload release in response to pathological cues in the TSCI microenvironment. Dual-responsive design further enhances temporal precision, enabling early anti-inflammatory effects and late neuroregeneration. The ROS-responsive injectable hydrogel (CMV-RM) developed by Chen et al. can detect increases in local ROS levels in the TSCI area, release nanoantioxidant drugs in a controlled manner, and precisely regulate the inflammatory microenvironment while protecting neurons from oxidative stress (Fig. 9b) [52]. In general, intelligent response is achieved through structural design of stimuli-sensitive units, energy-transducing components, or reversible chemical bonds. These materials show great potential in targeted delivery, biomimetic scaffold engineering, and dynamic microenvironment regulation, opening new avenues for precise spinal cord repair. However, a key bottleneck remains: the complex in vivo environment often compromises responsiveness, and balancing responsiveness, release stability, biodegradability, and biosafety is highly challenging, thereby limiting its clinical translation.Fig. 9Intelligent response materials for TSCI repair. a, In the SCI model, MAFG stimulates spinal cord regeneration by inputting and amplifying the local external magnetic field. b, CMV-RM hydrogel can first respond to the oxidative stress microenvironment related to SCI and release nanomedicines to alleviate inflammation and protect neurons, thereby playing a role in the early stage of SCI. Intelligent response materials for TSCI repair. a, In the SCI model, MAFG stimulates spinal cord regeneration by inputting and amplifying the local external magnetic field. b, CMV-RM hydrogel can first respond to the oxidative stress microenvironment related to SCI and release nanomedicines to alleviate inflammation and protect neurons, thereby playing a role in the early stage of SCI. Selection of the intervention timing Tissue engineering therapies for TSCI are generally delivered either immediately after injury (during the acute phase) or with a delay of one to two weeks (during the subacute phase). Clinically, treatment should ideally be administered during the acute or subacute phase. Early intervention is often impractical due to limited medical resources, unstable patient conditions, and complex complications [219]. Most animal studies implant biomaterials immediately after injury. This strategy does not match real clinical treatment workflows, yet it reduces individual variations in injury responses and improves experimental repeatability. Lesions in the acute phase are characterized by severe inflammation and massive cell death. Biomaterials can sequester inflammatory mediators and reactive oxygen species while simultaneously protecting transplanted cells, thereby significantly enhancing their survival and engraftment [220,221]. A small number of trials perform implantation several hours or days after injury. This design better reflects clinical treatment, but secondary surgery introduces additional tissue damage [222]. In contrast, therapeutic intervention during the subacute phase, defined as 1–2 weeks after injury, is associated with superior tissue repair outcomes. During this period, lesion pathology reaches a state of relative stability, neuroinflammatory activity declines significantly, and the local microenvironment becomes increasingly conducive to regeneration. Delaying intervention until this stage circumvents the inhibitory influence of acute-phase inflammatory dynamics on biomaterial functionality, thereby enabling more effective cyst volume reduction, robust axonal regeneration, and improved functional recovery. Consequently, the subacute phase represents the currently optimal temporal window for tissue engineering–based interventions [223]. Regulation of TSCI repair by biomaterial mechanical cues The mechanical properties of biomaterials are core physical factors that regulate nerve repair and microenvironmental remodeling following TSCI. They mediate cellular mechanotransduction. Additionally, they regulate crucial pathological processes, such as neuroinflammation, glial scar formation, axonal regeneration, and myelin repair, thereby determining the efficacy of repair and the clinical translation potential of tissue engineering scaffolds. Tissues of the central nervous system demonstrate significant mechanical heterogeneity. The stiffness of the gray matter in the spinal cord is roughly twice that of the white matter [224]. Moreover, the mechanical baseline varies greatly among species, and rat spinal cord tissue is significantly stiffer than mouse spinal cord tissue [77]. These differences increase the complexity of achieving accurate mechanical biomimetic design. Ideal nerve repair materials possess two core functions: first, transmitting specific mechanical signals to activate cellular mechanotransduction pathways; second, constructing biomimetic mechanical microenvironments that promote the proliferation, maturation, and differentiation of nerve cells, thereby supporting the orderly remodeling of nerve tissue [225]. Therefore, biomaterials with mechanical properties similar to those of the native spinal cord are more conducive to tissue repair after TSCI [32]. Stiffness is the most mature and critical mechanical parameter for TSCI repair. The degree of mechanical matching between substrates directly influences cellular behavior, inflammatory responses, and the quality of axonal regeneration. Under physiological conditions, nerve cells are located on soft substrates with a stiffness ranging from 0.1 to 100 kPa. Deviating from this physiological stiffness range can easily lead to pathological changes [226]. Stiff biomaterials cause mechanical mismatch with spinal cord tissues. They continuously activate astrocytes and microglia, exacerbate foreign body reactions and glial activation, and promote glial scar formation, which physically impedes axonal regeneration [78,227]. In vitro experiments have confirmed that soft substrates promote the outgrowth and branching of spinal cord neuronal processes, thereby creating favorable conditions for nerve remodeling [228]. Nerve repair requires an optimal stiffness window rather than merely a lower stiffness. Relevant experiments show that 15% w/v GelMA hydrogel with a stiffness of 51.45 kPa effectively promotes the ordered growth and structural integrity of axons in injured sites. Its repair effect is superior to that of a low-stiffness hydrogel (15.12 kPa), confirming that appropriate mechanical constraints optimize axonal regeneration [229]. Precise mechanical matching between substrates and cells is crucial for regulating neuronal behaviors and ensuring repair outcomes [230]. In addition, substrate stiffness and surface physical structures modulate macrophage adhesion, migration, and polarization, thereby remodeling the immune microenvironment to assist nerve repair [231]. Besides static stiffness, viscoelasticity and elastic recovery are crucial dynamic mechanical properties. They can adapt to the spinal cord's physiological dynamic deformation and maintain stable, long-term repair microenvironments. The spinal cord undergoes continuous reciprocating deformation induced by respiration and body movement in vivo. Biomaterials with excellent elastic recovery can rapidly restore their original morphology after mechanical loading. They avoid residual deformation-induced stress accumulation and reduce persistent mechanical stimulation that causes abnormal glial activation. Material viscoelasticity combines elastic fixation and viscous relaxation. It buffers interfacial traction stress caused by spinal cord micromovement, inhibits excessive microglial activation and sustained inflammatory responses, and maintains neuronal survival and microenvironmental stability. Degradation kinetics should be optimized in concert with dynamic mechanical properties, as some synthetic scaffolds produce cytotoxic degradation products, thereby limiting their in vivo application [232]. In addition to core mechanical parameters, the surface topography and rheological properties of materials interact with mechanical performance to optimize the nerve repair microenvironment. Surface topography directly regulates neuronal adhesion, spreading, arrangement, morphological remodeling, and gene expression [233]. Optimized topographical matching effectively improves neurological functional recovery after TSCI [234]. Meanwhile, the excellent rheological properties endow hydrogels with injectable capacity. They can precisely fill injured lesions in a minimally invasive manner, avoid secondary surgical damage, stabilize defective areas through adaptive mechanical performance, and construct stable scaffold carriers for nerve repair [214]. TSCI repair demonstrates evident time-dependent characteristics. Tissues display distinct mechanical states at different pathological stages, which imposes temporal requirements for the mechanical adaptation of materials. Spinal cord tissues undergo significant softening during the acute and subacute stages. Ultra-soft hydrogel (1.5 kPa) is well adapted to the softened mechanical state of early-injured tissues, facilitates the formation of vascularized nerve tissues, and meets the repair requirements of the acute phase [235]. In the chronic stage, dense, stiff glial scars form in injured areas, creating a mechanically inhibitory microenvironment. This hinders cell migration, angiogenesis, and axonal regeneration. Lesion cavities and scar fibrosis worsen over time, further increasing the difficulty of repair [13]. Scaffolds with adaptive stiffness, favorable viscoelasticity, and gradient mechanical structures improve the stiffened scar microenvironment, weaken mechanical inhibition, and provide mechanical support for nerve tissue remodeling and neural circuit reconstruction in the chronic stage. Dynamically tunable mechanical materials designed based on pathological staging can enable precise temporal intervention. Ultra-soft, high-rheology materials can reduce secondary damage and inhibit inflammation during the acute stage. Moderately stiffened scaffolds can offer structural support for axonal extension and myelin regeneration in the subacute stage. Gradient mechanical structures can break the mechanical inhibition of scars and promote the remodeling of neural circuits in the chronic stage. The inherent coupling effect of biomaterial mechanical parameters hinders precise mechanical biomimetic design. Polymer crosslinking density determines substrate stiffness and simultaneously changes multiple physical and chemical properties, including porosity, degradation rate, and swelling behavior. Independent regulation of a single mechanical index cannot be achieved, which can easily cause an imbalance in material stability and biocompatibility [236]. The inherent mechanical heterogeneity of nerve tissues and the temporal evolution of mechanics following injury further complicate precise mechanical adaptation. Moreover, the interspecies mechanical differences pose a significant barrier to clinical translation. The moduli of rat and human spinal cords differ by orders of magnitude. The optimal mechanical parameters verified in animal experiments do not translate to human pathological microenvironments, greatly restricting the clinical translation of basic research results [78]. Multifunctional modification based on mechanical adaptation compensates for the limitations of single mechanical regulation. For instance, a hyaluronic acid hydrogel composite with magnetic microparticles enables non-invasive neural regulation through favorable mechanical matching. It modulates the mechanosensitive ion channel Piezo2 and relieves neuropathic pain induced by mechanical disorders, thereby enriching the regulatory mechanisms of mechanical biomaterial repair [237]. In summary, the multidimensional mechanical properties of biomaterials transmit mechanical signals and, together with structural and degradable characteristics, comprehensively regulate neuroinflammation, glial scar formation, and nerve regeneration after TSCI. Current research has evolved from single, static stiffness optimization to dynamic, temporal, and multi-parameter synergistic biomimicry. However, several challenges remain, including the difficult, coupled regulation of mechanical parameters, imperfect interspecies adaptation systems, and insufficient targeted mechanical interventions for chronic injury. Future development of time-responsive intelligent mechanical scaffolds, multi-signal-coupled biomimetic microenvironments, and optimized interspecies mechanical adaptation systems will overcome existing technical bottlenecks and enhance the clinical translation potential of nerve repair biomaterials. Engineering platforms for TSCI repair In TSCI repair, tissue engineering aims to restore spinal cord tissue structure and function through the rational use of materials and techniques. While the functional materials described in Section 5.3 overcome individual pathological barriers through physicochemical modification, engineering platforms integrate these materials into deployable systems with distinct therapeutic roles matched to the spatiotemporal phases of TSCI. Specifically, nanoparticles primarily address acute-phase microenvironmental dysregulation by enabling targeted drug delivery across the BSCB and responsive modulation of oxidative stress and inflammation; hydrogels conform to irregular lesion cavities in the acute and subacute phases, providing mechanical matching and localized cargo release; biological scaffolds provide durable structural bridging and anisotropic guidance for chronic-phase axonal regeneration across cystic cavities and glial scars; and spinal cord organoids offer biomimetic tissue replacement and neural circuit reconstruction for restoring functional connectivity. Currently, the main technical approaches of tissue engineering for TSCI repair include nanoparticles, hydrogels, biological scaffolds, and SCOs. The following sections will systematically elaborate on the design principles, implementation strategies, and representative research progress of each technical approach within this pathology-driven framework. Nanoparticles Given the urgent need to modulate the acute inflammatory and oxidative microenvironment and to deliver therapeutics across the compromised BSCB, nanoparticles serve as precision nanocarriers for spatiotemporally controlled intervention. According to their material composition, nanoparticles can be classified into metal, polymer, protein, inorganic, and lipid nanoparticles [238,239]. Characterized by dimensions spanning the 1 to 1000 nm range, they possess singular advantages, including exceptional biocompatibility, high payload-loading capacity, and the ability to traverse disrupted biological barriers. These nanoparticles can be administered via multiple routes, including local injection, intravenous injection, oral delivery, and local implantation with biomaterials, and have broad application prospects in the treatment of TSCI [240,241]. Notably, some nanoparticles themselves exhibit therapeutic activity. For example, Liu et al. found that zinc oxide nanoparticles can act as neuroprotective agents by reducing oxidative stress and inhibiting neuronal apoptosis following axonal transection, thereby exerting direct neuroprotective effects [242]. Additionally, PEGylated nanoparticles, liposomes, and poly(lactic-co-glycolic acid) (PLGA) nanoparticles have become ideal drug carriers due to their surface charge characteristics and large specific surface area, which significantly improve the stability, solubility, and transmembrane transport efficiency of drugs [243]. In recent years, the composite system comprising drugs/cytokines and nanomaterials has achieved precise delivery and controlled release of therapeutic agents, making substantial progress in the field of TSCI treatment [[244], [245], [246]]. For instance, Jiang et al. developed an intelligent nanodrug delivery system, aFGFND, which can enhance the protective effect of aFGF, prolong its circulation time in the blood, and promote efficient BSCB delivery, thereby accelerating spinal cord repair [247]. Beyond the precise delivery and controlled-release capabilities of nanomaterial-drug/cytokine composite systems, nanoparticles can also achieve active targeted delivery through surface functionalization. For example, Li et al. designed a TAT-TMP-NPs delivery system based on the pathological characteristic of neutrophil recruitment to the injury site after TSCI. Modifying the nanoparticles with the TAT peptide enabled their uptake by neutrophils and their migration to the TSCI injury site, thereby achieving targeted drug release [248]. Nevertheless, drug administration routes, including intravenous, oral, and local injection, still encounter challenges such as low targeting efficiency to the lesion, short duration of action, and insufficient effective dose [249,250]. Consequently, researchers have combined nanoparticles with biomaterials to achieve in situ transplantation and intelligent response-based release in the injury area [251]. Ma et al. designed a cell-specific nanoparticle system, namely hydrogel-MG1-MM@Candesartan-Gel, which selectively and sustainably delivered the angiotensin II type 1 receptor antagonist candesartan to pro-inflammatory microglia at the injury site (Fig. 10) [252].Fig. 10Nanoparticle Repair of TSCI. Types of nanoparticles: metal nanoparticles, polymer nanoparticles, protein nanoparticles, inorganic nanoparticles, and lipid nanoparticles; Strategies for the delivery of nanoparticles: nanoparticles alone, loading with drugs, surface modification, and loading on biomaterials; Delivery mode of nanoparticles: local injection, intravenous injection, oral delivery, and loading implantation with biomaterials. Nanoparticle Repair of TSCI. Types of nanoparticles: metal nanoparticles, polymer nanoparticles, protein nanoparticles, inorganic nanoparticles, and lipid nanoparticles; Strategies for the delivery of nanoparticles: nanoparticles alone, loading with drugs, surface modification, and loading on biomaterials; Delivery mode of nanoparticles: local injection, intravenous injection, oral delivery, and loading implantation with biomaterials. Meanwhile, nanoparticles can serve as receivers and converters of various signal stimuli. When used in synergy with physical stimuli such as ultrasound, they can enhance therapeutic effects. Research has demonstrated that ultrasound can promote the differentiation of neural stem cells. When combined with nanoparticles, it can significantly enhance therapeutic efficacy through a multi-level amplification mechanism [[253], [254], [255], [256]]. Zhang et al. used ultrasound-driven lithium PDA@ZnO nanoparticles to promote neural stem cell differentiation in the injured area, thereby significantly restoring motor, sensory, and autonomic nerve functions after TSCI [257]. Nanoparticles, through surface repair and in combination with macromolecular drugs and biomaterials, enhance the stability and targeting of these drugs, facilitating their passage through the BSCB and demonstrating great potential for clinical translation [258]. The combined application of nanoparticles and physical stimuli is particularly noteworthy. This synergistic strategy not only enhances the effect of surgical intervention but also minimizes tissue trauma [259]. Nevertheless, issues such as the intrinsic physicochemical properties of nanoparticles, their in vivo metabolic kinetics, and long-term safety of clearance remain key bottlenecks that restrict their clinical translation [260]. Hydrogels Hydrogels, a type of biomaterial similar to “jelly” with high water content, possess precisely tunable mechanical properties that can match those of natural spinal cord tissue, making them increasingly favored in tissue engineering for TSCI repair [148,261]. Owing to their injectability, conformability, and soft mechanics, hydrogels are particularly suited for filling irregular cystic cavities and modulating the hostile microenvironment during the acute and subacute phases of TSCI. Hydrogels can be embedded in situ into spinal cord defects, where they exert tissue-adhesion and mechanical-support effects while also providing a microenvironment for cells to obtain nutrients and exchange substances. Meanwhile, by loading drugs, cells, or bioactive substances, hydrogels can achieve multiple therapeutic goals, including regulating immune responses, promoting the survival and differentiation of transplanted stem cells, facilitating axonal regeneration and myelination, protecting neurons, enhancing vascularization, and reducing scar formation, ultimately contributing to TSCI repair (Fig. 11) [262,263]. For instance, Thompson et al. mixed the cytoplasmic matrix of astrocytes derived from rat pluripotent stem cells with HA hydrogel and implanted the composite into TSCI sites. Two weeks post-implantation, the authors observed a significant reduction in glial scar dimensions, a marked decrease in pro-inflammatory macrophage/microglia infiltration, and enhanced axonal penetration into the lesion core, while also successfully supporting V2a interneuron transplantation and functional synaptic reconnection [264]. Similarly, Afroozi et al. used a chitosan hydrogel to load melatonin, thereby prolonging drug release and addressing the short action and retention time of melatonin and similar drugs in TSCI repair, thereby providing a novel strategy for drug-based TSCI treatment [265]. In addition to biologically derived hydrogels (e.g., collagen and sodium alginate hydrogels), artificially designed peptide self-assembling hydrogels have attracted considerable attention in recent years. Compared with traditional hydrogels, peptide hydrogels offer greater controllability [[266], [267], [268]]. For example, peptide sequences with anti-ROS, anti-inflammatory, cell-adhesion, or differentiation-promoting properties can be incorporated into peptide hydrogels, enhancing their ability to respond to the pathological cascade reactions following TSCI [[269], [270], [271]]. Zhou et al. integrated the natural human plasma tripeptide GHK into the peptide sequence (FFFGHK), endowing the peptide hydrogel with potent antioxidant and anti-inflammatory functions. This hydrogel is an injectable, biodegradable, non-swelling, and single-component self-assembling peptide hydrogel that does not require photo-crosslinking. It promotes repair of the damaged microenvironment characterized by ROS and inflammation, thereby facilitating neural regeneration [272]. In summary, hydrogels, with their controllable physicochemical properties, excellent biocompatibility, and multifunctional drug-loading capacity, have become one of the most commonly used technical platforms in tissue engineering-based TSCI repair.Fig. 11Hydrogel Repair of TSCI. Hydrogels can carry drugs, cells, and bioactive substances to repair TSCI in situ at the injury site. The main pathways of hydrogel-mediated TSCI repair include regulating immune responses; promoting the survival and differentiation of transplanted stem cells; promoting axonal regeneration and myelination; protecting neurons; promoting vascularization; and reducing scar formation. Hydrogel Repair of TSCI. Hydrogels can carry drugs, cells, and bioactive substances to repair TSCI in situ at the injury site. The main pathways of hydrogel-mediated TSCI repair include regulating immune responses; promoting the survival and differentiation of transplanted stem cells; promoting axonal regeneration and myelination; protecting neurons; promoting vascularization; and reducing scar formation. Biological scaffolds For chronic TSCI characterized by large tissue defects, cystic cavitation, and dense glial scarring, biological scaffolds provide the robust mechanical support and directional topographical cues necessary for long-distance axonal bridging. Pore geometry, mechanical stiffness, and surface topography are core physical properties that dominate regenerative outcomes [273]. Pore sizes around 30 μm facilitate cell infiltration and microvascular formation, while pores below 100 μm promote neural differentiation [274,275]. Rational pore structure and matched mechanical properties alleviate secondary injury and inhibit glial scar formation [276]. Oriented microchannel or fibrous topography further promotes ordered axonal elongation and neural tissue remodeling [277]. Biological scaffolds can be fabricated using diverse techniques, including electrospinning, phase separation, template synthesis, and 3D printing [278]. Based on their morphological structures, they can be classified into fibrous, single-channel, multi-channel, and microchannel scaffolds. Beyond serving as crucial conduits for material exchange and nutrient transport, biological scaffolds also act as excellent carriers for bioactive factors, drugs, and cells (Fig. 12). Stem cell transplantation often lacks spatial specificity, leading to cell loss or failure to anchor at the injury site, which significantly impairs the repair effect. Notably, biological scaffolds can effectively address these issues. For example, Zheng et al. designed a porous SF scaffold loaded with neural stem cells, which substantially improved the survival rate of transplanted cells, providing a potential clinical strategy for TSCI repair [279]. Among these scaffold types, microchannel nanofiber scaffolds are widely used in tissue engineering due to their larger specific surface area, which promotes cell adhesion and ingrowth [280]. For instance, Alves-Sampaio et al. implanted poly(3,4-ethylenedioxythiophene)-coated carbon microfibers (PEDOT-MFs) into transected rat spinal cords; these scaffolds promoted cell migration and the longitudinal alignment of axons, thereby facilitating tissue healing, angiogenesis, and axonal regeneration [281]. In addition, the 3D structure of biological scaffolds exhibits a high degree of biomimetic similarity to the natural extracellular matrix, thereby providing an ideal microenvironment for cell growth and functional expression [282,283]. Compared with hydrogels, a notable advantage of biological scaffolds is their stronger mechanical support performance and topological growth guidance.Fig. 12Repair of TSCI with Biological Scaffolds. The assembly methods of biological scaffolds include electrospinning, phase separation, self-assembly, 3D printing, and template synthesis. The classification of biological scaffolds comprises fibrous, single-channel, multi-channel, and microchannel scaffolds. Repair of TSCI with Biological Scaffolds. The assembly methods of biological scaffolds include electrospinning, phase separation, self-assembly, 3D printing, and template synthesis. The classification of biological scaffolds comprises fibrous, single-channel, multi-channel, and microchannel scaffolds. Spinal cord organoids To overcome the fundamental limitation of dissociated cell transplantation, the inability to reconstruct native tissue architecture and functional neural circuits, SCOs provide pre-formed, biomimetic tissue units for structural and functional replacement in chronic-phase TSCI. The spinal cord is a highly complex organ composed of more than 20 types of cells, including diverse subtypes of neurons, glial cells, and other cell categories [284]. It forms intricate motor and sensory circuits together with the surrounding tissues. The high complexity of the spinal cord has driven the rapid development of SCOs technology, making it one of the leading strategies for TSCI repair. The construction of SCOs typically uses induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) as the initial cells. In recent years, significant breakthroughs have been made in the direct reprogramming of somatic cells. For example, Xu et al. generated spinal cord organoids by reprogramming astrocytes, which then established new synaptic connections with host neurons in a mouse model of TSCI, facilitating reconnection of completely injured spinal cords [285]. Currently, the construction strategies of SCOs include extracellular matrix scaffolds, bioreactors, hanging drop, organoid-on-a-chip technology, low-adhesion plates, and magnetic levitation [286]. Biomaterials such as Matrigel, extracellular matrix, collagen, hydrogels, and synthetic proteins provide three-dimensional biomimetic support for SCOs, mimicking the in vivo developmental microenvironment and offering a novel platform for studying spinal cord pathological mechanisms and regenerative medicine applications. For instance, Ma et al. used a Matrigel–collagen type II composite channel system to construct SCOs, which supported long-term in vitro culture and promoted functional recovery after implantation in complete transection TSCI [287]. In the field of neural tissue engineering, SCOs represent a cutting-edge platform that integrates seed cells, biomaterial scaffolds, and microenvironment regulation. Compared with dissociated cell transplantation, SCOs possess native-like tissue architecture, neuronal networks, and synaptic connections, making them ideal grafts for replacing damaged spinal cord tissue and reconstructing neural circuits [288]. In vitro, SCOs serve as powerful tissue engineering models for drug screening, neurotrophic factor evaluation, and gene function analysis, recapitulating key processes of spinal cord development, circuit formation, and maturation [289]. For example, Miura et al. established a cortical–spinal–muscle organoid assembly that enabled in vitro observation of neural interactions and signal transmission, providing a biomimetic model for studying neural communication and disease mechanisms [290]. Compared with conventional stem cell transplantation, SCOs technology shows potential to alleviate several long-standing obstacles, including low cell survival, uncontrolled differentiation, and insufficient structural integration. However, it does not fully overcome these challenges, and the tumorigenic risk remains a safety concern that requires further evaluation. Despite rapid advances, SCOs-based therapy still faces substantial and unresolved challenges. These include high batch-to-batch variability and structural heterogeneity, limited neuronal and functional maturation, lack of intrinsic vascularization, poor host–graft integration in injured spinal cord tissue, potential immunogenicity upon transplantation, low methodological reproducibility, and unknown long-term biosafety [291]. Further investigations are required to improve the controllability, maturity, vascularization, and functional integration of SCOs before clinical translation can be realistically considered. Nevertheless, as a rapidly advancing branch of neural tissue engineering, SCOs exhibit extremely broad application prospects. They provide a unique strategy for personalized tissue-engineered spinal cord grafts, in vitro pathological models, and the development of next-generation regenerative therapies. With further optimization of culture systems, biomaterial composite construction, vascularization engineering, and maturation-promoting strategies, SCOs are expected to become a core tissue-engineering tool for bridging the gap between laboratory research and clinical translation in TSCI repair [292]. The continuous development of SCOs technology offers a versatile platform for studying spinal cord development, disease modeling, and personalized treatment, while its unique advantages in replicating key features of in vivo neural development warrant further exploration (Fig. 13) [291,293,294]. Unlike nanoparticle-mediated drug delivery or hydrogel-based cavity filling, SCOs aim to replace lost neural tissue and directly reestablish synaptic connectivity, thereby addressing the chronic-phase challenge of functional circuit reconstruction that passive materials alone cannot achieve.Fig. 13SCOs for TSCI Repair. The cell sources for SCOs include induced iPSCs, ESCs, and gliocyte; The methods of SCOs production encompass extracellular matrix scaffold, bioreactors, the hanging drop, organoid-on-a-chip platform, the low-adhesion plate, and the magnetic levitation; The biomaterials used for constructing 3D scaffolds: extracellular matrix, collagen, hydrogel, and recombinant proteins; The roles of SCOs in TSCI repair are as follows: In vivo, SCOs can replace region-specific cells and establish neural circuit connections and develop synaptic linkages; In vitro, they can simulate physiological structures of the spinal cord, and processes of circuit formation and development, and evaluate drugs, biological factors, and genetic elements in TSCI repair. SCOs for TSCI Repair. The cell sources for SCOs include induced iPSCs, ESCs, and gliocyte; The methods of SCOs production encompass extracellular matrix scaffold, bioreactors, the hanging drop, organoid-on-a-chip platform, the low-adhesion plate, and the magnetic levitation; The biomaterials used for constructing 3D scaffolds: extracellular matrix, collagen, hydrogel, and recombinant proteins; The roles of SCOs in TSCI repair are as follows: In vivo, SCOs can replace region-specific cells and establish neural circuit connections and develop synaptic linkages; In vitro, they can simulate physiological structures of the spinal cord, and processes of circuit formation and development, and evaluate drugs, biological factors, and genetic elements in TSCI repair. Clinical translation Advances in tissue engineering have facilitated the clinical translation of biomaterial scaffolds, and preliminary clinical trials have confirmed their safety and demonstrated promising therapeutic effects in patients with TSCI. A wide range of biomaterial carriers, ranging from autologous tissue grafts to synthetic polymers and natural collagen-based scaffolds, have been clinically explored. These constructs are typically integrated with stem cell or primary cell transplantation to promote neural regeneration. Although scaffold-based tissue engineering strategies have yielded promising clinical outcomes, substantial obstacles still hinder their large-scale translation into clinical practice. This section summarizes recent advances in clinical research and major obstacles to clinical translation, including standardized manufacturing requirements, surgical feasibility, regulatory constraints, and the gap between preclinical outcomes and clinical application. We finally propose a complete staged translational roadmap linking laboratory material optimization to standardized routine clinical practice. Clinical case table of tissue engineering for TSCI treatment Multiple clinical studies have validated the safety and preliminary efficacy of biomaterial-based tissue engineering approaches for TSCI repair (Table 5). In 2001, Brazilian researchers performed olfactory mucosa autografts in 7 patients with chronic complete spinal cord injury (AIS A) at the C4–T6 level. After an 18-month follow-up, the treatment showed favorable safety profiles. Two patients experienced an improvement from AIS A to AIS C, with overall gains in motor and sensory functions, as well as partial recovery of bladder and anal sphincter function [295]. A 2014 North American clinical study implanted the Neuro-Spinal Scaffold (NSS) in 19 patients with acute complete thoracic TSCI at levels T2–T12. Six-month follow-up outcomes confirmed the safety and feasibility of NSS implantation; 7 of the 16 evaluable patients showed improvement in AIS grade [296]. A 2020 Chinese clinical trial recruited 40 patients with acute complete cervical TSCI, who underwent implantation of collagen scaffolds in combination with human umbilical cord mesenchymal stem cells. At the 1-year follow-up, the patients showed improved AIS grades and enhanced daily living activities. Moreover, restoration of intestinal and urinary functions, formation of new nerve fiber connections, and recovery of neuroelectrophysiological activity were observed in these patients [297]. In 2021, Chinese researchers treated 66 patients with acute or chronic complete spinal cord injury using NeuroRegen scaffolds loaded with mesenchymal stem cells or bone marrow mononuclear cells. During a 2–5-year follow-up period, no severe implant-related adverse complications were reported. Patients with acute TSCI achieved partial recovery in sensation, autonomic nerve function, and motor capacity. Meanwhile, patients with chronic TSCI exhibited improved sensory perception, physiological reflexes, and limb mobility [298].Table 5Clinical case table of tissue engineering for TSCI treatment (2000-2026).Table 5YearNation/Region areaTissue engineering materialSample sizesSite and degree of InjuryTypes of injuryFollow-up visitAssessment criteriaPrimary efficacy (AIS/function)Ref.12001BrazilOlfactory Mucosa Autografts7●Neurological levels: C4–T6●Lesions ranging:1-6 cmChronic (0.6–6.5 years)AIS: A18 months●MRI●EMG●AIS neurological●Otolaryngological evaluations●Relatively safe●Two patients with AIS A became AIS C●Motor and sensory scores universally improved●Bladder and anal sphincter function partially recovered[295]22014North AmericaNeuro-Spinal Scaffold (NSS)19●Neurological levels: T2–T12●Lesion range: 1- 6 cmAcuteAIS: A6 months●MRI●NLI●AIS Impairment Scale●Safe and feasible●7 out of 16 patients achieved AIS grade improvement[296]32020ChinaCollagen scaffold + human umbilical cord-mesenchymal stem cells40Complete cervical injuriesAcute12 months●MRI●MEP●SSEP●AIS motor and sensory scores●ADL score●AIS scores and activities of daily living scores were increased●Bowel and urinary functions were recovered●New nerve fiber connections were formed●Electrophysiological activity was recovered[297]42021ChinaNeuroRegen Scaffolds + Mesenchymal Stem Cells/Bone Marrow Mononuclear Cells66●Neurological levels: C4–T3●Lesion range: 0.6- 9 cmAcute: 15 patientsChronic: 51 patientsAIS: A24–60 months●AIS Impairment Scale●MRI●EMG●SSEP●No severe transplantation-related adverse events●Partial sensation, visceral nerve, and motor function recovered in acute cases●Improved sensation, reflex, and limb activity observed in chronic cases[298]MRI: Magnetic Resonance Imaging; EMG: Electromyography; AIS: American Spinal Injury Association Impairment Scale; SSEP: Somatosensory Evoked Potentials. Table 5Clinical case table of tissue engineering for TSCI treatment (2000-2026).Table 5YearNation/Region areaTissue engineering materialSample sizesSite and degree of InjuryTypes of injuryFollow-up visitAssessment criteriaPrimary efficacy (AIS/function)Ref.12001BrazilOlfactory Mucosa Autografts7●Neurological levels: C4–T6●Lesions ranging:1-6 cmChronic (0.6–6.5 years)AIS: A18 months●MRI●EMG●AIS neurological●Otolaryngological evaluations●Relatively safe●Two patients with AIS A became AIS C●Motor and sensory scores universally improved●Bladder and anal sphincter function partially recovered[295]22014North AmericaNeuro-Spinal Scaffold (NSS)19●Neurological levels: T2–T12●Lesion range: 1- 6 cmAcuteAIS: A6 months●MRI●NLI●AIS Impairment Scale●Safe and feasible●7 out of 16 patients achieved AIS grade improvement[296]32020ChinaCollagen scaffold + human umbilical cord-mesenchymal stem cells40Complete cervical injuriesAcute12 months●MRI●MEP●SSEP●AIS motor and sensory scores●ADL score●AIS scores and activities of daily living scores were increased●Bowel and urinary functions were recovered●New nerve fiber connections were formed●Electrophysiological activity was recovered[297]42021ChinaNeuroRegen Scaffolds + Mesenchymal Stem Cells/Bone Marrow Mononuclear Cells66●Neurological levels: C4–T3●Lesion range: 0.6- 9 cmAcute: 15 patientsChronic: 51 patientsAIS: A24–60 months●AIS Impairment Scale●MRI●EMG●SSEP●No severe transplantation-related adverse events●Partial sensation, visceral nerve, and motor function recovered in acute cases●Improved sensation, reflex, and limb activity observed in chronic cases[298]MRI: Magnetic Resonance Imaging; EMG: Electromyography; AIS: American Spinal Injury Association Impairment Scale; SSEP: Somatosensory Evoked Potentials. Clinical case table of tissue engineering for TSCI treatment (2000-2026). ●Neurological levels: C4–T6 ●Neurological levels: C4–T6 ●Lesions ranging:1-6 cm ●Lesions ranging:1-6 cm ●MRI ●MRI ●EMG ●EMG ●AIS neurological ●AIS neurological ●Otolaryngological evaluations ●Otolaryngological evaluations ●Relatively safe ●Relatively safe ●Two patients with AIS A became AIS C ●Two patients with AIS A became AIS C ●Motor and sensory scores universally improved ●Motor and sensory scores universally improved ●Bladder and anal sphincter function partially recovered ●Bladder and anal sphincter function partially recovered [295] [295] ●Neurological levels: T2–T12 ●Neurological levels: T2–T12 ●Lesion range: 1- 6 cm ●Lesion range: 1- 6 cm ●MRI ●MRI ●NLI ●NLI ●AIS Impairment Scale ●AIS Impairment Scale ●Safe and feasible ●Safe and feasible ●7 out of 16 patients achieved AIS grade improvement ●7 out of 16 patients achieved AIS grade improvement [296] [296] ●MRI ●MRI ●MEP ●MEP ●SSEP ●SSEP ●AIS motor and sensory scores ●AIS motor and sensory scores ●ADL score ●ADL score ●AIS scores and activities of daily living scores were increased ●AIS scores and activities of daily living scores were increased ●Bowel and urinary functions were recovered ●Bowel and urinary functions were recovered ●New nerve fiber connections were formed ●New nerve fiber connections were formed ●Electrophysiological activity was recovered ●Electrophysiological activity was recovered [297] [297] ●Neurological levels: C4–T3 ●Neurological levels: C4–T3 ●Lesion range: 0.6- 9 cm ●Lesion range: 0.6- 9 cm ●AIS Impairment Scale ●AIS Impairment Scale ●MRI ●MRI ●EMG ●EMG ●SSEP ●SSEP ●No severe transplantation-related adverse events ●No severe transplantation-related adverse events ●Partial sensation, visceral nerve, and motor function recovered in acute cases ●Partial sensation, visceral nerve, and motor function recovered in acute cases ●Improved sensation, reflex, and limb activity observed in chronic cases ●Improved sensation, reflex, and limb activity observed in chronic cases [298] [298] MRI: Magnetic Resonance Imaging; EMG: Electromyography; AIS: American Spinal Injury Association Impairment Scale; SSEP: Somatosensory Evoked Potentials. Overall, existing clinical evidence demonstrates that tissue engineering strategies possess favorable biocompatibility and can elicit modest yet promising neurological improvements in patients with spinal cord injury. Collectively, all the aforementioned clinical studies demonstrate that sensory and autonomic nerve recovery is markedly superior to motor functional recovery after spinal cord injury. This finding suggests that although biomaterials can effectively modulate the local inhibitory microenvironment and facilitate tissue integration, they fail to overcome the intrinsic barriers to corticospinal tract regeneration, thereby restricting axonal regrowth and synaptic circuit reconstruction [299]. Improvements in AIS grades may result from spontaneous neural plasticity or rehabilitative interventions rather than genuine axonal regeneration, especially in incomplete spinal cord injuries with residual neural pathways [300]. To date, no tissue-engineered products have received official regulatory approval for routine clinical use in TSCI repair. Key clinical determinants affecting translation outcomes Tissue engineering strategies for TSCI repair have shown promising regenerative effects in preclinical studies; however, their clinical translation remains hindered by diagnostic, manufacturing, biological, and regulatory hurdles [301]. Early clinical trials have yielded variable and modest functional outcomes, reflecting the substantial challenges involved in translating bench-side regenerative technologies into standardized, reliable clinical treatments. We analyze the primary barriers to such clinical translation below. Diagnostic uncertainty Diagnostic uncertainty compromises accurate patient screening and individualized treatment. Clinicians still lack a unified, consensus-based definition of acute complete TSCI [302,303]. Spinal shock inevitably distorts assessments of injury severity. It often leads to incomplete neurological injuries being misclassified as complete TSCI, which hinders rational surgical planning [304]. Conventional imaging and electrophysiology cannot reliably differentiate necrotic from viable spinal cord tissue, hindering the standardization of precise intraoperative debridement [305]. Moreover, no validated clinical biomarkers are currently available to predict the regenerative potential of neural synapses or the reconstruction of functional neural circuits after transplantation, leaving postoperative efficacy assessments subjective and lacking quantitative evidence [306,307]. Manufacturing scaling and physicochemical standardization Shifting from laboratory-scale fabrication to standardized, GMP-compliant production introduces formidable material-specific bottlenecks [308]. First, the sterilization of advanced biomaterials remains a critical paradox: standard autoclaving or gamma irradiation severely degrades the tertiary structure of natural polymers (e.g., collagen, hyaluronic acid) and cleaves synthetic polymer chains, altering their degradation kinetics. Conversely, chemical sterilants such as ethylene oxide raise significant concerns about the entrapment of toxic residues within porous matrices. Second, long-term storage and shelf-life extension present severe logistical hurdles. For cell-seeded scaffolds, cryopreservation at ultra-low temperatures requires cryoprotectants like DMSO, which necessitate complex, sterile washing procedures in the operating theater before implantation to avoid localized neurotoxicity. For acellular scaffolds, maintaining long-term hydration, structural integrity, and bioactivity without inducing premature hydrolysis is equally challenging. These constraints directly exacerbate batch-to-batch inconsistency. Minor fluctuations in ambient humidity, crosslinking temperature, or automated mixing speed during scale-up lead to unpredictable variations in critical quality attributes (CQAs), such as localized stiffness, interconnected porosity, and localized cell-loading density. Crucially, current manufacturing lacks non-destructive, high-throughput inline analytical tools to verify the micro-topographical fidelity of engineered scaffolds before clinical dispatch. Detrimental post-traumatic microenvironment The detrimental post-traumatic microenvironment hinders endogenous neural repair and compromises graft survival [309]. Pro-inflammatory cytokines present at the injury site diminish the paracrine neuroprotective effects of transplanted stem cells [310]. Moreover, scaffold implantation may provoke foreign-body reactions and activate the complement system, thereby exacerbating neuroinflammatory injury [311]. In terms of cell safety, iPSC-derived cell products carry potential tumorigenic risks, and gene-edited cells may cause off-target effects [312]. Most existing clinical trials provide only 6–12 months of follow-up, which is insufficient to monitor delayed adverse events or identify long-term prognostic biomarkers. Due to considerable interindividual variation in the stage, severity, and anatomical location of TSCI, generic tissue engineering strategies fail to address the diverse pathological profiles, ultimately leading to heterogeneous treatment responses. Preclinical-to-clinical therapeutic prediction gaps Marked discrepancies between preclinical findings and clinical applications undermine the reliability of predicting therapeutic effects. Most preclinical studies use rodent thoracic contusion and compression models, which cannot fully recapitulate human TSCI pathologies. Unlike these animal models, clinical TSCI predominantly presents as an incomplete cervical injury and is often accompanied by multiple systemic traumas [313]. Marked interspecies disparities in intrinsic neural regenerative capacity and immune profiles continue to hinder the translation of findings from animal experiments into clinical practice [69]. While non-human primate models exhibit higher clinical translatability, their utility is substantially hampered by prohibitive costs, ethical constraints, and small sample sizes, resulting in a scarcity of high-quality translational data. Clinically, the low incidence and high heterogeneity of TSCI pose challenges to the implementation of large-scale, standardized, randomized controlled trials. Current clinical studies are mostly single-center, small-sample, and single-arm trials lacking sham-surgery controls [314]. Heterogeneous evaluation metrics and the difficulty of distinguishing treatment-induced improvements from spontaneous neurological recovery collectively undermine the robustness of clinical evidence. Regulatory and surgical barriers to clinical translation The ambiguous regulatory standards and complex surgical constraints act as obstacles to clinical adoption. Scaffold-cell composite constructs represent a classic regulatory challenge; they are designated as Combination Products by the US FDA (involving joint review by CBER and CDRH via the stringent Premarket Approval [PMA] pathway) and classified as Advanced Therapy Medicinal Products (ATMPs) under the Tissue Engineered Products category in Europe. The lack of harmonized global standards for evaluating the separate and synergistic mechanisms of material and cellular components creates unpredictable regulatory hurdles [315]. This regulatory gridlock is worsened by the absence of highly sensitive, clinically meaningful endpoints. Historically, clinical trials have relied heavily on the American Spinal Injury AIS grading. However, the AIS scale is notoriously insensitive to subtle yet life-changing neurological gains, such as a localized 1-2 level segment recovery in cervical injuries or changes in neuropathic pain profiles. To establish robust efficacy, future trials must transition from macroscopic motor scales to multi-dimensional, validated functional metrics. These include the Spinal Cord Independence Measure (SCIM) for daily living autonomy, the Graded Redefined Assessment of Strength, Sensibility and Plasticity (GRASSP) for upper-extremity function, and quantitative urodynamic monitoring to objectively measure bladder compliance. From the surgical perspective, acute TSCI is often accompanied by spinal instability, while chronic TSCI presents dense intramedullary scar adhesions, both of which increase the technical difficulty of accurate and safe scaffold implantation. Existing biomaterial scaffolds and minimally invasive delivery approaches cannot adequately withstand the physiological pulsations and flexion-extension movements of the spinal cord. Moreover, single-modal treatments address merely one pathological cascade after TSCI. For multimodal combinatorial approaches that integrate biomaterials, cell transplantation, pharmacotherapy, and neuromodulation, consistent standards for dosage, treatment timing, and procedural sequence remain lacking, thereby limiting large-scale, standardized clinical translation. Clinical translational roadmap of tissue engineering for TSCI The successful clinical translation of tissue engineering for TSCI repair requires interdisciplinary convergence among materials science, cell biology, neuroimmunology, and neurosurgery. To resolve the multi-dimensional translational barriers and transform effective preclinical biomaterial designs into repeatable routine clinical treatments, we put forward a practical translational roadmap with five core modules (Fig. 14):1.Preclinical material design: Biomaterials are designed according to stage-specific pathological demands of acute anti-inflammation, subacute axonal sprouting and chronic scar bridging. Researchers adjust key physicochemical parameters such as stiffness, viscoelasticity, anisotropic topography, multifunctional bioactivity and degradation kinetics. In vitro mechanistic tests and layered animal assessments follow, including preliminary screening in rodent models and predictive verification in non-human primate TSCI models.2.GMP standardized manufacturing and quality control: This module unifies fabrication parameters, standardizes sterilization and storage procedures, detects critical quality attributes, and ensures batch-to-batch consistency to stabilize product performance.3.Clinical preparation and individualized patient stratification: Clinicians adopt unified global diagnostic standards for TSCI. They combine MRI and electrophysiological examinations, apply predictive biomarkers for neural regeneration, and select matched implantation timing for different pathological stages.4.Intraoperative implementation and multimodal combination therapy: Researchers develop phase-matched combined regimens of scaffolds, stem cells, drugs, and neuromodulation. Standard surgical procedures and real-time intraoperative safety monitoring are also included.5.Long-term clinical observation and regulatory approval: Longitudinal observation lasts two to five years to track delayed adverse reactions. Researchers adopt measurable neurological evaluation indicators and conduct large-scale randomized controlled trials with sham operation groups. Harmonized evaluation standards apply to composite scaffold medical devices before official approval for routine clinical use.Fig. 14Schematic clinical translational roadmap of tissue engineering for TSCI. The workflow covers five sequential and interconnected modules: preclinical material design; GMP-standardized manufacturing and quality control; clinical preparation and individualized patient stratification; intraoperative implementation and multimodal combination therapy; and long-term clinical observation and regulatory approval. This systematic framework addresses core translational bottlenecks, including interspecies prediction gaps, batch inconsistency, ambiguous diagnostic criteria, surgical limitations, and imperfect regulatory systems, thereby bridging laboratory material optimization and the development of reproducible clinical TSCI treatments. 1.Preclinical material design: Biomaterials are designed according to stage-specific pathological demands of acute anti-inflammation, subacute axonal sprouting and chronic scar bridging. Researchers adjust key physicochemical parameters such as stiffness, viscoelasticity, anisotropic topography, multifunctional bioactivity and degradation kinetics. In vitro mechanistic tests and layered animal assessments follow, including preliminary screening in rodent models and predictive verification in non-human primate TSCI models. Preclinical material design: Biomaterials are designed according to stage-specific pathological demands of acute anti-inflammation, subacute axonal sprouting and chronic scar bridging. Researchers adjust key physicochemical parameters such as stiffness, viscoelasticity, anisotropic topography, multifunctional bioactivity and degradation kinetics. In vitro mechanistic tests and layered animal assessments follow, including preliminary screening in rodent models and predictive verification in non-human primate TSCI models. 2.GMP standardized manufacturing and quality control: This module unifies fabrication parameters, standardizes sterilization and storage procedures, detects critical quality attributes, and ensures batch-to-batch consistency to stabilize product performance. GMP standardized manufacturing and quality control: This module unifies fabrication parameters, standardizes sterilization and storage procedures, detects critical quality attributes, and ensures batch-to-batch consistency to stabilize product performance. 3.Clinical preparation and individualized patient stratification: Clinicians adopt unified global diagnostic standards for TSCI. They combine MRI and electrophysiological examinations, apply predictive biomarkers for neural regeneration, and select matched implantation timing for different pathological stages. Clinical preparation and individualized patient stratification: Clinicians adopt unified global diagnostic standards for TSCI. They combine MRI and electrophysiological examinations, apply predictive biomarkers for neural regeneration, and select matched implantation timing for different pathological stages. 4.Intraoperative implementation and multimodal combination therapy: Researchers develop phase-matched combined regimens of scaffolds, stem cells, drugs, and neuromodulation. Standard surgical procedures and real-time intraoperative safety monitoring are also included. Intraoperative implementation and multimodal combination therapy: Researchers develop phase-matched combined regimens of scaffolds, stem cells, drugs, and neuromodulation. Standard surgical procedures and real-time intraoperative safety monitoring are also included. 5.Long-term clinical observation and regulatory approval: Longitudinal observation lasts two to five years to track delayed adverse reactions. Researchers adopt measurable neurological evaluation indicators and conduct large-scale randomized controlled trials with sham operation groups. Harmonized evaluation standards apply to composite scaffold medical devices before official approval for routine clinical use. Long-term clinical observation and regulatory approval: Longitudinal observation lasts two to five years to track delayed adverse reactions. Researchers adopt measurable neurological evaluation indicators and conduct large-scale randomized controlled trials with sham operation groups. Harmonized evaluation standards apply to composite scaffold medical devices before official approval for routine clinical use. Schematic clinical translational roadmap of tissue engineering for TSCI. The workflow covers five sequential and interconnected modules: preclinical material design; GMP-standardized manufacturing and quality control; clinical preparation and individualized patient stratification; intraoperative implementation and multimodal combination therapy; and long-term clinical observation and regulatory approval. This systematic framework addresses core translational bottlenecks, including interspecies prediction gaps, batch inconsistency, ambiguous diagnostic criteria, surgical limitations, and imperfect regulatory systems, thereby bridging laboratory material optimization and the development of reproducible clinical TSCI treatments. Collectively, this multi-stage closed-loop framework addresses all major translational limitations discussed above, bridges lab-based material optimization and repeatable standardized clinical intervention for TSCI, and further consolidates the clinical feasibility of the pathology-guided biomaterial design framework proposed throughout this review. Discussion TSCI remains a formidable clinical therapeutic challenge. Researchers have developed numerous interventions to reconstruct injured tissue and restore neurological function [316,317]. The progressive and intricate pathological processes triggered by injury greatly limit the therapeutic efficacy of single-target treatments, hindering satisfactory tissue regeneration and functional restoration [318]. In contrast, multimodal combined therapies address multiple regenerative obstacles through synergistic interactions, exhibiting superior application potential and the promise of substantially improving clinical repair outcomes. These facts highlight the necessity of strengthening interdisciplinary cooperation to advance TSCI research further. As an emerging interdisciplinary field that integrates life sciences, materials science, and engineering, tissue engineering has progressed from simple structural repair to the construction of functional tissues and organs. With the ongoing advances in research and technological innovation, tissue engineering has demonstrated multidimensional therapeutic potential for TSCI repair. In TSCI repair, tissue engineering uses biomaterials selected for their excellent biocompatibility, tissue compatibility, and controlled degradability to mimic the mechanical properties of the native spinal cord, thereby achieving structural biomimicry. These biomaterials act as scaffolds to bridge lesion sites, fill cystic cavities formed by necrotic tissue, and facilitate neuronal migration, differentiation, and regeneration [169,319]. When stem cells, immune cells, and other seed cells are delivered using tailored biomaterial carriers, transplanted cell survival and retention improve markedly. This optimization substantially boosts cell-based therapeutic effects and accelerates the formation of functional neural relay circuits [196,320]. Furthermore, biomaterial carriers can encapsulate neuroprotective, neurotrophic, and regenerative agents to sustain drug release and enhance treatment efficacy [321]. By tuning the material degradation behavior and kinetics, researchers can precisely control the timing, sequence, and dosage of the bioactive factors loaded, enabling personalized cascade treatment regimens [322,323]. Material structural modification also guides neural regeneration. The incorporation of conductive or magnetic particles, combined with physical intervention, creates innovative treatment modalities and viable rehabilitation solutions for post-injury functional recovery [324]. Given the progressive pathological changes after traumatic spinal cord injury, combined therapeutic schemes are widely adopted, though simple component pairing cannot guarantee synergistic benefits. Genuine synergism generates therapeutic effects that exceed the sum of individual interventions, relying on intrinsic mechanistic coordination rather than passive co-administration [318]. Selecting matched biomaterials, seed cells, cytokines, and drugs to trigger ordered therapeutic cascades remains the central research priority in this field. Treatment outcomes depend on both component selection and synergistic integration. Aligning intervention schedules with dynamic pathological progression also profoundly influences the efficacy of multimodal therapy [325]. Currently, standardized evaluation approaches remain insufficient to distinguish true neural regeneration from temporary functional compensation or spontaneous natural recovery. A critical weakness within the current evidence base is an over-reliance on behavioral improvement as a surrogate for regenerative repair. Rodent BBB scores have no direct human correlates; human AIS grading cannot distinguish therapeutic efficacy from spontaneous recovery, especially during the subacute phases [326]. Notably, histological observations of axonal sprouting—commonly regarded as a positive regenerative sign in preclinical research—do not equate to functional synaptic integration or the formation of behaviorally competent neural circuits [327]. To address this bottleneck, the field requires standardized, biomaterial-adaptive evaluation endpoints that integrate structural imaging (diffusion tensor tractography), electrophysiological assessments of conduction (transcranial magnetic stimulation-evoked potentials), and patient-reported autonomic function metrics. This multimodal evaluation system enables accurate identification of genuine neural regeneration rather than compensatory functional improvement [328,329]. Establishing a rigorous developmental roadmap is essential for accelerating the clinical translation of tissue-engineering-based TSCI therapies. Prior preclinical validation using standardized large-animal models is strongly recommended to reduce interspecies discrepancies, verify biological safety, and confirm the stability of therapeutic effects. Therapeutic strategies should be dynamically tailored to distinct pathological stages of TSCI to sequentially alleviate secondary injury, modulate local inflammatory microenvironments, and facilitate the reconstruction of damaged neural circuits. Furthermore, clinical interventions can be personalized according to individual differences in injury severity and lesion location, while specific biomarkers can assist in screening eligible patients for regenerative therapy. Continuous optimization of biomaterial manufacturing and surgical implantation techniques is also necessary to ensure consistent product performance and enhance operational feasibility. Ultimately, unified industrial specifications and comprehensive, multidimensional evaluation criteria are indispensable for objective assessment of outcomes, avoiding the one-sided overestimation of repair efficacy based solely on behavioral recovery. Encouraging preclinical advances have been made in tissue engineered TSCI repair, whereas multiple hurdles still hinder clinical conversion. Complex pathological mechanisms, together with clear anatomical, immunological, and regenerative differences across species, limit the ability of small-animal models to recapitulate human pathological features. Building standardized large animal evaluation systems and exploring translational mechanisms effectively bridge basic research and clinical practice. Though the transformation process remains challenging, sustained multidisciplinary innovation will enable tissue engineering to deliver viable therapeutic solutions for injured patients. Ethics approval and consent to participate This article is a review and does not involve any new studies with human or animal subjects performed by the author. Therefore, ethical approval and informed consent were not required for this work. CRediT authorship contribution statement Chengcheng Luan: Investigation, Writing – original draft, Writing – review & editing. Dong Ming: Writing – review & editing. Xiaosong Gu: Funding acquisition, Resources, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.